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CHAPTER 1
INTRODUCTION

Inflammatory Breast Cancer. Inflammatory breast cancer (IBC) is the
most lethal type of breast cancer with a three-year survival rate of 42% as
compared to 85% for non-IBC (Chang et al., 1998b). The incidence of IBC is
relatively low but varies depending on geographic region.

For example, an

analysis by Hance et. al reported that IBC accounts for approximately 2.5% of all
breast cancer cases in the USA (Hance et al., 2005) whereas in parts of northern
Africa rates may be as high as 10% (Boussen et al., 2010). The unique clinical
presentation and symptoms of primary IBC, described below, are quite distinct
from non-IBC (Walshe and Swain, 2005) and because it is rare, clinicians are
less familiar with the disease. Upon physical examination, a palpable discrete
mass is absent in many patients and IBC is often misdiagnosed as mastitis, a
benign bacterial infection. Therefore, accurate and early diagnosis is critical due
to the aggressiveness and rapid onset of IBC. In 2010, an international panel of
leading experts recommended that the clinical consensus for a minimal standard
diagnosis of IBC include erythema occupying at least one-third of the breast,
hardening and retraction of the nipple, dimpling (peau d’orange) of the skin
caused by enlarged hair-follicle pits that does not respond to antibiotic treatment
(Dawood et al., 2010) (Figure 1.1). More than half to 85% of patients present
with

axillary

or

supraclavicular

	
  

lymph

node

metastases
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Figure 1.1. Clinical signs of IBC and variations in presentation. (A) Primary
IBC with synchronous bilateral erythema with minimal breast edema. (B) An
African American IBC patient with increased breast size and peau d’orange with
minimal erythema. (Robertson et al., 2010)
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(Walshe and Swain, 2005). Indeed, classification of IBC is considered at least
Stage IIIB or higher depending on nodal status and the presence of distant
metastases (Edge et al., 2010).
Mammographic and ultrasonographic imaging are both important for IBC
diagnosis and disease assessment and often reveal the absence of an
underlying discrete mass or lump.

Ultrasonographic evaluation has proved

significant for detection of skin, pectoral muscle and axillary lymph node
involvement and also for revealing masses. Masses may be otherwise masked
by accompanying inflammatory changes such as skin thickening and stromal
coarsening and/or increased density when evaluated by mammography
(Gunhan-Bilgen et al., 2002).

The clinical manifestation and characteristic

imaging profile of the involved breast are thought to reflect dermal lymphatic
invasion, in which invasive cellular aggregates or tumor emboli in dermal
lymphatics block drainage of these vessels.
IBC is an aggressive and fatal invasive breast cancer and therefore
studies have focused on establishing epidemiological risk factors, identifying
molecular features and defining the specific biology of IBC. Risk factors highly
associated with IBC include younger age at diagnosis, high body mass index and
African American ethnicity (Chang et al., 1998a; Levine and Veneroso, 2008).
Over-expression of the Ras superfamily member RhoC and loss of WISP3 may
be two key and related events in the development of IBC (Miao et al., 2003). IBC
tumors, in comparison to non-IBC tumors, have a higher occurrence of p53 gene
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mutations (Riou et al., 1993; Gonzalez-Angulo et al., 2004), increased
expression of angiogenic and lymphangiogenic factors including VEGF, IL-6, IL-8
and VEGF receptor 3 (Van der Auwera et al., 2004), and a greater incidence of
HER2 positivity and EGF receptor (Guerin et al., 1989; Parton et al., 2004). In
IBC, high levels of the cysteine protease cathepsin B correlate with increases in
numbers of metastatic lymph nodes (Nouh et al., 2011). Caveolin-1, which was
initially hypothesized to be a tumor suppressor in breast cancer (Bouras et al.,
2004), is highly expressed in both IBC cells and tissues (Van Laere et al., 2005;
Van den Eynden et al., 2006; Nouh et al., 2011). Recent data suggest that high
expression of caveolin-1 is a characteristic of triple-negative and other basal-like
breast cancers (Elsheikh et al., 2008), including IBC of a basal phenotype.

Caveolin-1 and Caveolae.

Caveolin-1, a 22-kDa protein, was first

identified in Rous sarcoma virus transfected fibroblasts as a phosphorylation
substrate of v-Src (Glenney, 1989).

Caveolin-1 belongs to a family of three

highly conserved proteins. Caveolin-1 and caveolin-2 are expressed in most
tissues and caveolin-3 is muscle specific. The caveolins have a hairpin loop
structure that is inserted into the inner leaflet of the plasma membrane with the
N- and C-termini exposed to the cytoplasm (Glenney and Soppet, 1992).
Cholesterol binds caveolin-1 via a putative cholesterol-binding domain and this
interaction is thought to facilitate its oligomerization (Murata et al., 1995).
Assembly of caveolin-1 oligomers at the plasma membrane forms the structure
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and scaffold of caveolae (Monier et al., 1995; Fernandez et al., 2002) with the
integrity and function of caveolae dependent on membrane cholesterol (Rothberg
et al., 1992). First identified in the 1950s by electron microscopy, caveolae are
omega-shaped plasmalemmal invaginations approximately 50-100 nm in
diameter.

Caveolae

are

specialized

cholesterol-

and

sphingolipid-rich

microdomains that are distinct from other lipid rafts as well as from the general
plasma membrane and clathrin-coated vesicles (Schnitzer et al., 1995b;
Anderson and Jacobson, 2002).

The lipid raft model originated from

observations that glycosphingolipids first cluster in the Golgi apparatus before
being sorted to the apical surface of epithelial cells (Simons and van Meer,
1988).

Subsequent studies demonstrated that sphingolipid-cholesterol rafts

(including caveolae) are insoluble in the detergent Triton X-100 at 4°C, resulting
in detergent–insoluble or –resistant membranes. As a result of the elevated lipid
content, these detergent-insoluble membranes float to a light buoyant density on
sucrose gradients (Brown, 1994) along with associated proteins. This has led to
purification techniques and use of cholesterol-modulating agents for the study of
lipid rafts and caveolae (Sargiacomo et al., 1993; Smart et al., 1995; Song et al.,
1996). In prostate cancer models, strategies to disrupt cholesterol-rich structures
have elucidated their associated proteins and functions in tumor progression [for
review see (Di Vizio et al., 2008)]. For example, targeted disruption of lipid rafts
with cholesterol binding agents inhibits EGF receptor and Akt1 phosphorylation
and reduced survival of prostate cancer cells (Zhuang et al., 2002; Oh et al.,

	
  

	
  

2007).
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Alternatively inhibiting cholesterol biosynthesis alters lipid raft

composition, i.e. decreased cholesterol content and phosphorylated Akt, inhibits
Akt pathway signaling and induces apoptosis in prostate cancer cells and
xenografts (Zhuang et al., 2005). Recently, quantitative proteomics is being used
to map the lipid raft proteome, studies which may identify tumor biomarkers and
therapeutic targets (Staubach and Hanisch, 2011).

Specific Functions of Caveolae and Caveolin-1.

Caveolae play

functional roles in both endocytosis and transcytosis (Montesano et al., 1982;
Schnitzer et al., 1994; Schnitzer et al., 1995a; Schnitzer, 2001).

Caveolae

associated signaling molecules have also been identified: a number of
heterotrimeric G proteins (Oh and Schnitzer, 2001), non-receptor tyrosine
kinases (Liu et al., 1997) and Ras (Rizzo et al., 1998).

Thus, caveolae

compartmentalize signaling pathways and may act as cell surface structures for
regulated signal transduction. Caveolin-1 protein directly interacts with many of
the aforementioned as well as several other proteins and lipids, e.g. insulin
receptor and GM1 [for review see (Liu et al., 2002a)] indicating its role in lipid
transport, lipid trafficking and signal transduction. We propose that caveolae also
serve as sites on the cell surface linking signaling pathways and proteolytic
networks that are involved in tumor invasion.

	
  

	
  

7

Proteases and Their Receptors in Caveolae.

We previously

hypothesized that the high levels of caveolin-1 expression in bladder, colon,
esophageal and prostate cancers promote cell surface proteolytic events that
lead to extracellular matrix (ECM) degradation and tumor invasion [for review see
(Cavallo-Medved and Sloane, 2003)].

Annexin II, a member of a family of

membrane-binding proteins that bind to negatively charged phospholipids in a
calcium-dependent manner [for review see (Gerke and Moss, 2002), localizes to
caveolae in many cell types (Sargiacomo et al., 1993; Lisanti et al., 1994;
Cavallo-Medved et al., 2005). Annexin II (or p36), like caveolin-1, is a v-Src
substrate (Soric and Gordon, 1986) and exists both as a monomer and in a
heterotetrameric complex, referred to as the annexin II heterotetramer (AIIt). AIIt
consists of two subunits of annexin II, the heavy chain, bound to a homodimer of
S100A10 (also called p11), the light chain. The amino terminus of annexin II
contains the binding site for its hydrophobic interactions with S100A10 (Rety et
al., 1999). The heavy chain, annexin II, is a collagen I binding protein (Santoro et
al., 1994). Chung et al. found that the annexin II tetramer interacts with an
alternatively spliced segment of tenascin C on the cell surface of U-251MG
human glioma cells (Chung and Erickson, 1994). Usually absent from most adult
tissues, tenascin C reappears in places of active tissue regeneration and cell
migration, i.e., in tumors and areas of wound healing (Mackie et al., 1988;
Koukoulis et al., 1991). The AIIt is a receptor for and regulatory complex of
plasminogen (MacLeod et al., 2003). Our laboratory demonstrated that the AIIt
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serves as a binding platform for cathepsin B on the surface of tumor cells (Mai et
al., 2000). More specifically, we have shown that in colon cancer cells cathepsin
B and AIIt localize in caveolae (Cavallo-Medved et al., 2003). Proteases of the
plasminogen cascade, specifically pro-urokinase plasminogen activator (prouPA) and its receptor uPAR have also been localized to caveolae (Stahl and
Mueller, 1995; Cavallo-Medved et al., 2005). These findings may be of functional
significance as cathepsin B is capable of processing the zymogen pro-uPA to its
active derivative uPA (Kobayashi et al., 1991), which in turn can activate
plasminogen bound to AIIt. A proteolytic pathway involving cathepsin B and uPA
has been identified upstream of plasminogen on the surface of a number of cell
lines (Kobayashi et al., 1992; Kobayashi et al., 1993; Guo et al., 2002).
Moreover, uPAR complexes with caveolin-1 via β1-integrin, an association that
has been shown to mediate uPAR-dependent adhesion and β1-integrin-induced
signal transduction (Wei et al., 1999; Schwab et al., 2001). Localization of these
enzymes and their receptors to caveolae supports the hypothesis that proteolytic
cascades may be initiated in caveolae and participate in tumor invasion via the
degradation of extracellular matrix components (Figure 1.2).

Cathepsin B: Intracellular Trafficking and Activity. Cathepsin B is a
ubiquitously expressed lysosomal cysteine protease of the papain family. In the
acidic lysosomal environment, cathepsin B functions in protein degradation in
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Figure 1.2. Proteases localize to caveolae at the surface of tumor cells.
Caveolae are distinct lipid microdomains that are small invaginations of the
plasma membrane formed by the oligomerization of the structural protein
caveolin-1. Cathepsin B, uPA and their respective receptors, the annexin II
heterotetramer and uPAR, localize at the tumor cell surface in caveolae. The
bidirectional interaction between cathepsin B and uPA is one example of a
proteolytic network clustering in caveolae that may affect tumor progression.
Arrows indicate cleavage events that activate pro-enzymes. Adapted from
(Rothberg et al., 2011).

	
  

	
  

10

mammalian cells, exhibiting broad substrate specificity (Mort and Buttle, 1997).
Some redundancy in function of cysteine cathepsins might explain why the
absence of cathepsin B is not lethal.

Analyses of knockout mice have

demonstrated significant roles for cathepsin B in trypsinogen activation in
pancreatitis and also TNF-alpha specific. Non-redundant functions of cathepsin
B suggest its involvement in processes of physiology and pathology (Guicciardi
et al., 2000; Halangk et al., 2000).
The single human cathepsin B gene is located on chromosome 8p22
(Fong et al., 1986; Fong et al., 1992). Cathepsin B mRNA is translated as a
preprocathepsin B on the rough endoplasmic reticulum. The signal recognition
prepeptide directs translated mRNA into the rough endoplasmic reticulum. Two
N-glycosylation sites, one within the 62 residue proregion and another present in
the heavy chain, are co-translationally glycosylated. Following cleavage of the
17 residue prepeptide, the inactive proenzyme moves through the ER and is
shuttled into the Golgi apparatus.

Normal trafficking of cathepsin B to the

lysosome follows the traditional mannose-6-phosphate pathway characteristic of
lysosomal enzymes.

Therefore, after entry into the Golgi complex, further

modification of cathepsin B carbohydrate moieties to phosphorylated mannose
residues enables recognition by membrane bound mannose-6-phosphate
receptors (MPR). In the trans-Golgi, the 300-kDa cation-independent CI-MPR
and

the

46-kDa

cation-dependent

CD-MPR

bind

the

phosphorylated

carbohydrate moieties of procathepsin B (Ludwig et al., 1993).

	
  

Normally
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procathepsin B is trafficked from the Golgi to the pre-lysosomal compartment of
late endosomes.

The slightly acidic pH of the late endosomes results in

dissociation of procathepsin B from MPRs.

Removal of phosphate by acid

phosphatase from the mannose-6-phosphate residues on cathepsin B prevents
its retrograde trafficking. In the late endosome maturation of the enzyme by
cleavage of the pro-region results in the 31-kDa active cathepsin B species
(Mach et al., 1992). Cathepsin B is next transported to perinuclear lysosomes,
where it normally functions in protein degradation and turnover of cellular
components.
Therefore, there are several forms of intracellular cathepsin B.

The

molecular weight of the inactive species is 43 or 46-kDa, depending upon
glycosylation. The active single chain form exists as a 31-kDa protein of 252
amino acids.

In some tissues, additional proteolytic cleavage of the 31-kDa

species occurs within the lysosome, the result of which is a double chain form
composed of a 25/26-kDa heavy chain and 5-kDa light chain, bound by a
disulfide linkage (Nishimura et al., 1988; Rowan et al., 1992). The difference in
heavy chain molecular weight, 25 or 26 kDa, is due to removal of a carbohydrate
moiety from the latter (Mach et al., 1992). The active site is within the 5-kDa light
chain of the double chain form. The double chain cathepsin B is also short two
amino acids in the heavy chain, a result of their cleavage during processing
(Figure 1.3).
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Figure 1.3. Cartoon illustrating the various cathepsin B species. Cathepsin
B mRNA is translated as preprocathepsin B. The signal recognition prepeptide
directs translated mRNA into the rough endoplasmic reticulum. The molecular
weight of the inactive procathepsin B species is 43 or 46-kDa, depending upon
glycosylation. Potential glycosylation sites are depicted as “Y”. The active single
chain form exists as a 31-kDa protein of 252 amino acids. In some tissues,
additional processing of the 31-kDa species by cleavage of a dipeptide occurs
within the lysosome, the result of which is a double chain form composed of a
25/26-kDa heavy chain and 5-kDa light chain that are linked by a disulfide bridge.
Adapted from (Cavallo-Medved and Sloane, 2003).
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Structurally, cathepsin B is a bilobal protein, containing two globular
domains, between which the active site and substrate-binding site are located. In
its active form, cathepsin B can act either as an endopeptidase, cleaving internal
peptide bonds, or an exopeptidase, by removing C-terminal dipeptides from a
substrate (Keppler and Sloane, 1996). Cathepsin B exhibits this dual peptidase
activity due to a flexible structural element within the molecule, the occluding
loop.

At acidic pH, this occluding loop partially blocks the active site of the

molecule, preventing large protein substrates from entering the active site and as
a

result

the

enzyme

exhibits

exopeptidase

activity,

specifically

carboxydipeptidase activity. In a neutral pH environment, the loop is displaced
and no longer blocks access of proteins to the active site, and therefore
cathepsin B can act as an endopeptidase cleaving peptide bonds within a
substrate.

Aberrant Trafficking of Cathepsin B.

In normal cells less than five

percent of the proenzyme is secreted (Hanewinkel et al., 1987). Unlike normal
cells, cancer cells secrete significantly greater amounts of latent pro- and mature
cathepsin B. This is observed in human malignancies of the breast (Poole et al.,
1978) and colon (Maciewicz et al., 1989) as well as gliomas (McCormick, 1993).
The normal location of lysosomes, and therefore cathepsin B, is perinuclear in
the region of the microtubule organizing center and in the apical pole of polarized
epithelial cells. There is altered intracellular distribution of the cathepsin B in
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tumors, leading to cathepsin B in vesicles throughout the cytoplasm and at the
cell periphery. As seen by cathepsin B staining of human colon cancer tissues,
there is a shift in localization from the apical pole of the cell to the inner basal
surface of the plasma membrane (Emmert-Buck et al., 1994). Not only is there a
change in localization as noted here, but also increased message, protein, and/or
activity are localized to regions of tumor invasion (Sinha et al., 1993; EmmertBuck et al., 1994; Visscher et al., 1994).
The mechanism for the aberrant intracellular localization of cathepsin B,
its trafficking to the cell surface and subsequent secretion are yet unknown
(Figure 1.4).

Experimental data support several hypotheses.

For example,

studies on macrophages and fibroblasts demonstrated that experimentally
lowering cytoplasmic pH causes lysosomes to move toward the cell periphery
(Heuser, 1989). This movement follows an alteration in microtubules, and does
not occur if cells are treated with the microtubule depolymerizing agent
nocodazole. When evaluating how malignant progression affects the intracellular
distribution and secretion of cathepsin B, Rozhin et al. incubated malignant cells
at slightly acidic pH. Not only did secretion of active cathepsin B increase and
intracellular levels decrease, but vesicles positive for cathepsin B localized to the
cell periphery.

These effects were inhibited by treatment with both taxol, a

microtubule stabilizer, and colchicine, a microtubule poison (Rozhin et al., 1994).
The studies suggest that modulating pH disrupts the microtubule cytoskeleton
resulting in the movement and even secretion of lysosomal constituents, i.e.,
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Figure 1.4. Classical and alternative trafficking pathways for cathepsin B.
This diagram illustrates the potential pathways of cathepsin B trafficking in either
normal or cancer cells. Normal trafficking of cathepsin B to the lysosome follows
the traditional mannose-6-phosphate pathway characteristic of lysosomal
enzymes, indicated by the black arrows. Cathepsin B mRNA is translated as a
preprocathepsin B on the RER, transported through the Golgi complex, to late
endosomes and finally to the lysosome. In tumor cells cathepsin B is still
trafficked to the lysosome, but is also trafficked by alternative pathways,
indicated by the red arrows: (1) Procathepsin B is secreted from tumor cells and
exists as either a soluble or membrane bound form. (2) Active cathepsin B may
also be translocated to the plasma membrane via secretory lysosomes that either
fuse with the plasma membrane or undergo exocytosis and secrete soluble
cathepsin B. The blue arrows indicate extracellular cathepsin B. Adapted from
(Cavallo-Medved and Sloane, 2003).
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release of active cathepsin B into the extracellular milieu. In vitro pH modulation
may be relevant as it closely imitates the acidic tumor microenvironment found in
vivo [for reviews, see (Wike-Hooley et al., 1984; Gillies et al., 2002)].
To understand cathepsin B functionality through qualitative analysis of
secretion and membrane association, our lab developed an assay for
measurement of cathepsin B activity in real time. Pericellular cathepsin B activity
was shown to be forty to fifty percent membrane associated (Linebaugh et al.,
1999). Other studies suggest that exocytosis of lysosomes is calcium mediated
or that a yet unknown endosome functions in secretion of active cathepsin B
(Rodriguez et al., 1997; Linebaugh et al., 1999; Andrews, 2000). Procathepsin B
secretion is thought to be independent of the secretory lysosome theory, i.e.,
secretion of active cathepsin B. Procathepsin B is secreted through the default
pathway as a result of the high levels of expression in tumors and swapping of
available MPRs (Roshy et al., 2003).

Molecular

Regulation

of

Cathepsin

B.

Molecular

regulatory

mechanisms controlling the biosynthesis of cathepsin B may play a role in the
divergent protein trafficking seen in malignancy. Gene amplification, increased
transcription, mRNA stability, use of alternative promoters, and alternative
splicing have all been shown to affect the levels and/or localization of cathepsin
B protein in pathologies [for review, see (Yan and Sloane, 2003)].

These

molecular changes at the genetic level resulting in elevated protein, aberrant
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localization, secretion, and in turn greater activity of cathepsin B, have been
noted in several tumor types such as brain, colorectal, lung and prostate (Yan et
al., 1998; Koblinski et al., 2000).
The cathepsin B transcript consists of at least 13 exons (Berquin et al.,
1995). The 5’-untranslated region includes exons 1, 2, and 25 bp of exon 3.
Translation of the preproprotein sequence begins at the initiation site within exon
3 and ends in exon 11, where the stop codon resides. The remainder of exon 11
and 12 constitute the non-coding 3’-untranslated region. Cao et al. were the first
to isolate full-length preprocathepsin B cDNA clones from a human tumor source
(Cao et al., 1994). In a later study, the same cDNA clones were assessed for
any structural modifications that might result in membrane association and
secretion of cathepsin B. Two new exons (exon 2a and exon 2b) and multiple
transcription initiation sites in the 5’-UTR were identified (Berquin et al., 1995).
The region upstream of exon 1 is high in GC content and lacks TATA and CAAT
boxes, characteristics of a housekeeping-type promoter. This suggests that the
cathepsin B gene may be constitutively expressed. This does not exclude the
possibility of transcriptional regulation at the cathepsin B promoter. Cathepsin B
expression and activity levels differ among tissue types or between normal and
malignant tissues suggesting tissue specific regulation (San Segundo et al.,
1986; Qian et al., 1989; Shuja et al., 1991). Within a region 200 base pairs
upstream of the initiation site there are six Sp1, four Ets, and one USF (E box)
binding sites (Jane et al., 2002). The presence of these additional elements may
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induce transcription at the cathepsin B promoter. Sp1 and Ets factors regulate
expression of cathepsin B in glioma (Yan et al., 2000). The same transcription
factors, e.g., Ets1, that regulate expression of cathepsin B in glioma are also
associated with components of a proteolytic cascade in this case uPA and
caspase 3 (Delannoy-Courdent et al., 1998; Liu et al., 2002b).

Cathepsin B in Malignancy. Pathologies associated with cathepsin B
include inflammatory airway diseases, acute pancreatitis, arthritis, and cancer
[for reviews, see (Reinheckel et al., 2001; Vasiljeva et al., 2007; Reiser et al.,
2010). Protease activity is important for tumor cell invasion and the many steps
of tumor progression. Cathepsin B and other proteases function in the cleavage
of enzymes secreted as inactive precursors, degradation of the basement
membrane, invasion of surrounding tissues, and also angiogenesis. There is a
substantial literature that supports a functional role for cathepsin B in malignancy
[for reviews, see (Gocheva et al., 2006; Mohamed and Sloane, 2006).
Cathepsin B expression and/or its activity is increased in several tumor
types.

These include carcinomas of the breast (Krepela et al., 1989), colon

(Campo et al., 1994), prostate (Sinha et al., 1995), lung (Sukoh et al., 1994) and
stomach (Watanabe et al., 1989), gliomas (Rempel et al., 1994), and melanomas
(Sloane et al., 1981). As is true for matrix metalloproteinases (MMPs) and serine
proteases (van Kempen et al., 2002; Netzel-Arnett et al., 2003), tumor stromal
interactions influence the expression and secretion of cathepsin B. Not only

	
  

	
  

19

tumor cells, but also other cells present in the tumor microenvironment, such as
inflammatory macrophages and fibroblasts, exhibit elevated levels of cathepsin B
(Campo et al., 1994; McKerrow et al., 2000). Our laboratory determined that
growth of human breast fibroblasts on collagen I alters cell morphology and
increases cathepsin B expression and secretion of procathepsin B (Koblinski et
al., 2002). In agreement with these findings Klose et al have observed that
cathepsin B protein levels and cellular localization are affected when highinvasive melanoma cells were cultured with collagen I, (Klose et al., 2006).
Increases in expression of uPA and MMPs are also observed when epithelial
cells, malignant cells, and stromal cells are cultured on various extracellular
matrices (Mauch et al., 1989; Khan and Falcone, 1997; Bafetti et al., 1998).
Thus, findings from several studies suggest that cell-matrix interactions play a
pivotal role in the regulation, localization, and activity of cathepsin B and many
other proteinases.
Cathepsin B cleaves a plethora of targets in the tumor mircoenvironment.
For example, cathepsin B is capable of degrading ECM components such as
type IV collagen, fibronectin, and laminin. The activity of cathepsin B, like other
tumor promoting proteases, has a more complex function in malignant
progression than once thought.

Mature active cathepsin B is capable of

converting these zymogens into their active derivatives: pro-MMP-3 (Murphy et
al., 1992), and pro-uPA (Kobayashi et al., 1991).

On the other hand,

procathepsin B activators include cathepsin D (van der Stappen et al., 1996),
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cathepsin G, tPA, uPA, and the elastases (Dalet-Fumeron et al., 1993; DaletFumeron et al., 1996).

Cathepsin B can also undergo glycosaminoglycan

facilitated autoactivation (Caglic et al., 2007).

Finally, cathepsin B, by

inactivation of endogenous protease inhibitors, indirectly increases the activity of
other proteases. For example, TIMP-1 and TIMP-2, the tissue inhibitors of matrix
metalloproteinases, and the serine protease inhibitor, antileukoproteinase, are
degraded by cathepsin B (Kostoulas et al., 1999; Taggart et al., 2001).
Cathepsin B participates in a complex proteolytic network to regulate
tumor progression [for review, see (Mason and Joyce, 2011)].

Moreover,

pericellular proteolytic pathways and signaling pathways converge to specific
regions on the cell surface, named caveolae. The annexin II tetramer, cathepsin
B, uPAR, uPA, and β1 integrin all localize to caveolae on the cell surface [for
review, see (Sloane et al., 2005)].

Not only do these proteins localize to

caveolae, they also facilitate interactions of their binding partners. Associations
between S100A10, the light chain of the AIIt, with both pro-cathepsin B and
plasminogen have been reported (Kang et al., 1999; Mai et al., 2000).

The

heavy chain, annexin II, is a collagen I binding protein (Santoro et al., 1994).
Also, the uPA:uPAR protein complex was shown to act as a ligand of β1 integrin
in Chinese hamster ovary cells (Tarui et al., 2003). Secretion and cell surface
association of both pro- and active cathepsin B observed in malignancy favor
conditions for its involvement in tumor invasion as well.
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Cathepsin B may play causal roles in tumor growth, not just invasion and
metastasis. Growth factors, such IGFs, FGFs, and TGF-βs, associated with ECM
components, control cell proliferation, differentiation, and synthesis of the
extracellular matrix. Cathepsin B remodeling of the extracellular matrix (ECM)
could influence the release of growth factors from matrix storage and even their
activation (Taipale and Keski-Oja, 1997). For example, cathepsin B proteolysis of
thyroglobulin mediates thyroid hormone liberation in thyroid epithelial cells (Brix
et al., 1996).

uPA and uPAR: Components of the Plasminogen Activation System.
The urokinase plasminogen activating system is a serine protease family
including uPA, its glycosyl phosphatidyl inositol-anchored receptor uPAR, soluble
uPAR, uPAR associated protein, plasminogen and the two inhibitors of the serine
proteinase inhibitor superfamily, plasminogen activator inhibitor-1 and -2. This
system is important for wound healing, tissue regeneration, immune response
and multiple aspects of neoplastic progression including cell adhesion, ECM
degradation and remodeling, migration, metastasis, growth at secondary tumor
site and neoangiogenesis [for reviews, see (Choong and Nadesapillai, 2003;
Duffy, 2004; Ulisse et al., 2009)]. uPA is secreted as a zymogen or pro-uPA and
binds to its receptor, uPAR, on the cell surface. Pro-uPA is processed to an
active two-chain form consisting of the uPAR binding A chain and catalytically
active B-chain (Robison and Collen, 1987; Gurewich, 2000). Biological activity of
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uPA is highly dependent on its binding to uPAR.

However, uPA-mediated

activation of plasmin and MMPs occurs in uPAR-deficient mice (Carmeliet et al.,
1998). uPAR-independent effects of uPA also include mitogenic stimulation of
quiescent melanoma cells

(Koopman et al., 1998).

Proteolytic cleavage of

plasminogen, the primary substrate of uPA, generates the serine protease
plasmin (Rickli, 1975), which in turn activates uPA, creating a feedback activation
loop between these proteases.

The key physiological role of plasmin is

fibrinolysis (Robison and Collen, 1987), but it also degrades ECM components
and activates MMPs in processes of angiogenesis and metastasis (Pepper,
2001; Rabbani and Mazar, 2001).
The plasminogen activation system is directly involved in metastatic
spread and reduced patient survival in breast cancer [for review, see (Han et al.,
2005).

More than 20 years ago uPA was first suggested as a marker of

aggressive breast cancer (Duffy et al., 1988). Since then many studies have
corroborated that uPA and uPAR are highly expressed in breast cancer patient
samples and are predictive of poor outcome (Grondahl-Hansen et al., 1995;
Grondahl-Hansen et al., 1997; Foekens et al., 2000). Plasminogen activation
and cell surface binding is regulated by uPA in breast cancer cells of high
invasive potential (Stillfried et al., 2007). In this study, the authors suggest that
uPA is a therapeutic target for the treatment of aggressive breast cancer. In
addition to malignant epithelial breast tissue, the plasminogen activation system
is also associated with stromal components of the tumor microenvironment, such
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as macrophages (Pyke et al., 1993), myofibroblasts (Nielsen et al., 1996) and
endothelial cells (Nielsen et al., 2001). MMTV-PymT transgenic mice deficient in
either uPA or plasminogen exhibit reductions in tumor cell spread to lymph nodes
and decreased lung metastasis (Bugge et al., 1998; Almholt et al., 2005).

Significance and Overall Hypothesis. My focus was to identify factors
that cause the aggressiveness and progression of IBC. Caveolae at the surface
of IBC cells may be involved in initiation of proteolytic pathways as a result of the
convergence of the plasminogen cascade with activation of the cysteine protease
cathepsin B.

My overall hypothesis was that cell surface association of the

cysteine protease cathepsin B, the serine proteases of the plasminogen cascade
and their binding partners in caveolae enhance cell surface proteolysis, and
ultimately, the aggressiveness of IBC cells. To test this hypothesis, I proposed
the following Specific Aims:

1: Determine whether there is active cathepsin B at the surface of
IBC cells. Breast cancer invasion has been linked to proteolytic activity at
the tumor cell surface. My working hypothesis is that active cathepsin B
localized to specialized regions of the cell surface, caveolae, contributes
to the aggressive IBC phenotype. We tested this hypothesis by treating
IBC cells with a highly selective cell impermeable cathepsin B inhibitor and
monitoring pericellular proteolysis by and invasion of IBC cells.
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2: Determine whether targeting caveolae, a specialized lipid raft, by
knockdown of the expression of caveolin-1 in IBC cells alters their
aggressive phenotype. My working hypothesis is that caveolae are a
functional component of the IBC phenotype. We tested this hypothesis by
knocking down the expression of caveolin-1 in the SUM149 IBC cell line.
We assessed how downregulation of caveolin-1 affected degradation of
ECM proteins, invasion through rBM and localization of proteins, including
those of proteolytic pathways that are associated with caveolae in other
cancer cells.

3: Determine whether targeting lipid rafts by treating IBC cells with
lovastatin alters their aggressive phenotype. My working hypothesis is
that lipid rafts are a functional component of the IBC phenotype.
Therefore, cholesterol depletion by treatment of IBC cells with a statin
drug (i.e., lovastatin) through the disruption of lipid microdomains,
including caveolae, will affect the IBC phenotype.

We tested this

hypothesis by treating IBC cell lines with lovastatin and monitored
degradation of ECM proteins, invasion through rBM and localization of
proteins, including those of proteolytic pathways that are associated with
caveolae in other cancer cells.
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CHAPTER 2
MATERIALS AND METHODS

Materials and Reagents. Tissue culture media and supplements: Ham’s
F-12 medium was purchased from Mediatech

(Manassas, VA); insulin,

hydrocortisone, ethanolamine, HEPES, 3,3′,5-triiodo-L-thyronine sodium salt,
sodium selenite, bovine serum albumin and antibiotics (penicillin/streptomycin)
from Sigma (St. Louis, MO); fetal bovine serum (FBS) from HyClone (Logan,
UT); trypsin-EDTA from GIBCO (Grand Island, NY); and the reconstituted
basement membrane Cultrex from Trevigen (Gaithersburg, MD).

Antibodies:

Monoclonal antibodies: β1-integrin was a kind gift from Dr. Kenneth Yamada
(National Institute of Dental and Craniofacial Research, National Institutes of
Health, Bethesda, MD); uPA and uPAR from American Diagnostica Inc.
(Stamford, CT); transferrin receptor from Invitrogen (Carlsbad, CA); β-tubulin
from the Developmental Studies Hybridoma Bank (National Institute of Child
Health and Human Development, University of Iowa, Iowa City, IA); and p36 and
p11 from BD Biosciences (Bedford, MA). Polyclonal antibodies: uPA and uPAR
were purchased from Abcam (Cambridge, MA) and caveolin-1 from BD
Biosciences.

The polyclonal antibody to cathepsin B was developed and

characterized in our laboratory (Moin et al., 1992).

Horseradish-peroxidase-

labeled goat anti-mouse and goat anti-rabbit IgG secondary antibodies were from
Pierce (Rockford, IL). The anti-rabbit Alexa Fluor 488 and donkey anti-mouse
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Alexa Fluor 555 were from Invitrogen. Other: Normal donkey serum, saponin,
doxycycline, Triton X-100, octylglucoside, dimethyl sulfoxide (DMSO), puromycin,
hexadimethrine bromide (polybrene), filipin III, lovastatin and all other chemicals
unless otherwise stated were from Sigma; (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium

bromide

(MTT),

4’,6-diamidino-2-phenylindole-

dihydrochloride (DAPI), Hoechst 33342 and DQ-collagen IV were from
Invitrogen;

benzyloxy-carbonyl-L-arginyl-L-arginine-4-methyl-7-coumarylamide

(Z-Arg-Arg-NHMec) was from Bachem (Torrance, CA); the cathepsin B inhibitor,
N-(l-3-trans-propyl-carbamoyloxir-ane-2-carbonyl)-L-isoleucyl-L-proline (CA074),
was

from

Peptides

International

(Louisville,

KY);

formaldehyde

from

Polysciences, Inc. (Warrington, PA); acrylamide and nitrocellulose membranes
were from BioRad (Hercules, CA); Ultrafree-0.5 PBGC Centrifugal Filter Units
with 5 kDa molecular weight cut off Biomax Membranes (Millipore, Billerica, MA);
micro-bicinchoninic acid (BCA) reagents were from Pierce (Rockford, IL);
enhanced chemiluminescent immunoblotting detection kit was from PerkinElmer
(Waltham, MA); OpenBiosystems TRIPZ shRNAmir Lentiviral Packaging system
and Non-silencing TRIPZ Lentiviral Inducible shRNAmir control particles were
from Open Biosystems, Thermo Fisher Scientific (Huntsville, AL); 8.0 µm
transparent PET membranes from BD Biosciences (Franklin Lakes, NJ);
DakoCytomation EnVision + Dual Link System-HRP (DAB +) were from Dako
(Carpinteria, CA); Permount® from Fisher Scientific (Pittsburgh, PA); and DiffQuik Stain Set was from Dade Behring (Newark, DE).
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Cell Lines and Tissue Culture. SUM149 and SUM190 human IBC cell
lines (a kind gift of Dr. Stephen Ethier, Wayne State University, Detroit, MI) and
the human IBC cell line, MDA-IBC-3 (provided by Dr. Wendy A. Woodward, The
University of Texas MD Anderson Cancer Center, Houston, TX), were cultured
as originally specified (Neve et al., 2006; Klopp et al., 2010) in Hams F-12 media
containing

5

mg/ml

insulin,

1

mg/ml

hydrocortisone,

antibiotics

(penicillin/streptomycin) and 5% (SUM149), 2% (SUM190) or 10% (MDA-IBC-3)
FBS.

Media for SUM190 cells were further supplemented with 5 mM

ethanolamine, 10 mM HEPES, 5 mg/ml transferrin, 6.6 ng/ml 3,3′,5-triiodo-Lthyronine sodium salt, 8.7 ng/ml sodium selenite and 1 mg/ml bovine serum
albumin. All cells were maintained in 5% CO2/humidified atmosphere at 37°C
with the media changed every two days.
All IBC cell lines were maintained and grown as a monolayer in tissue
culture flasks.

During log phase growth, cells were first washed twice with

phosphate buffered saline (PBS). For dissociation of cells from the culture flask,
0.25% trypsin-EDTA was added and cells were incubated at 37°C for either 2
minutes (SUM190 and MDA-IBC-3 cells) or 4 minutes (SUM149 cells). The cells
were then washed with 4 volumes of growth medium, transferred to a 15-ml
conical tube and centrifuged at 100 x g for 5 min. The media were aspirated and
the cell pellet resuspended in an appropriate amount of fresh growth media.
Cells were seeded in a new tissue culture flask. IBC cells were typically split at a
ratio of 1:3.

	
  

	
  

28

Preparation of cell lysates and conditioned media. IBC cells were
grown on plastic to 70% confluency and then serum-starved overnight.
Conditioned media were collected and centrifuged at 100 x g at 4 °C to remove
whole cells, and then re-centrifuged at 800 x g at 4 °C to remove cell debris. All
conditioned media samples were concentrated to equal volumes in Ultrafree-0.5
PBGC Centrifugal Filter Units with 5 kDa molecular weight cut-off Biomax
Membranes. Cells were harvested in lysis buffer (10 mM Tris, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 60 mM octylglucoside) and then passed ten times
through a syringe with a 20-gauge needle and centrifuged for 5 minutes at
10,000 x g at 4°C. Supernatants were recovered and protein concentrations
were quantified using micro-BCA reagents according to the manufacturer’s
instructions.

Preparation of 3D reconstituted basement membrane (rBM) overlay
cultures. Sixty-mm dishes were coated with 300 µl of rBM (Cultrex) and allowed
to solidify for 15 min at 37 °C. Suspensions of single cells (1 x 106) were seeded
on top of solidified rBM and grown in complete media containing 2% rBM. Within
24 hours, cells formed 3D spheroid structures.

Subcellular fractionation. Non-detergent and detergent based protocols
were used to prepare caveolae-enriched membrane fractions of IBC cells
(Cavallo-Medved et al., 2009). In the non-detergent based method, cells grown
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as a 2-dimensional (2D) monolayer on plastic (4 x 100-mm dishes) and in 3dimensions (3D) on rBM (4 x 60-mm dishes) for 2 and 5 days, respectively, were
washed with PBS and collected into 500 mM sodium carbonate buffer, pH 11.0.
Cells were homogenized in a Dounce homogenizer on ice and sonicated three
times for 10 seconds each. A discontinuous sucrose gradient was prepared as
previously detailed (Cavallo-Medved et al., 2009). Briefly, the cell homogenate
was mixed thoroughly with an equal volume of 90% (w/v) sucrose, then overlaid
with 35% (w/v) sucrose and 5% (w/v) sucrose and subsequently centrifuged
(185,000 x g) for 19 hours at 4 °C. One ml fractions were collected and equal
volumes of fractions 3-11 were analyzed by SDS-PAGE and immunoblotting
(Figure 2.1).
A successive detergent based method of cell fractionation was also
employed to separate Triton X-100-soluble (TS) and –insoluble (TI) membrane
fractions (Solomon et al., 1998).

3D cultures were prepared and grown, as

described above, for 2 days and thereafter washed with cold PBS, incubated with
300 µl of lysis buffer containing 1% Triton X-100 for 20 minutes on ice, and
collected and centrifuged at 14,000 x g for 10 min at 4 °C. The supernatant (TS
fraction) was collected and the pellet was resuspended in 300 µl of lysis buffer
containing 1% Triton X-100 plus 60 mM octylglucoside, incubated on ice for 20
minutes, passed through a syringe with a 21.5-gauge needle and centrifuged at
14,000 x g for 10 min at 4 °C. The supernatant (TI fraction) was recovered
(Figure 2.2.).
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Figure 2.1. Schematic for isolation of caveolae enriched fractions from IBC
cells, using non-detergent based lysis followed by subcellular fractionation
on a sucrose gradient.
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Figure 2.2. Schematic for isolation of caveolae-enriched fractions from IBC
cells, using detergent based lysis followed by subcellular fractionation.
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SDS-PAGE and immunoblotting.

Samples were equally loaded and

separated by SDS-PAGE (10 or 12%) under either reducing or non-reducing
conditions, transferred to a nitrocellulose membrane, blocked and immunoblotted
with primary antibodies against human cathepsin B (1:4000), β1-integrin
(1:3000), uPA (1:2000), uPAR (1:2000), caveolin-1 (1:4000) or β-tubulin (1:1500)
in TBS buffer (20 mM Tris, pH 7.5, 0.5 M NaCl) containing 0.5% Tween 20 and
5% (w/v) non-fat dry milk. After washing, membranes were immunoblotted with
secondary antibodies conjugated with horseradish peroxidase (1:10,000). After
washing, bound antibodies were detected by enhanced chemiluminescence
according to the manufacturer's instructions.

Cathepsin B activity assay. Cathepsin B activity was measured using
the synthetic fluorometric substrate Z-Arg-Arg-NHMec, as previously described
(Cavallo-Medved et al., 2003).

Briefly, equal-volume aliquots of TS and TI

fractions were incubated with activator buffer for 15 minutes at 37 °C. Following
this activation step, 150 mM Z-Arg-Arg-NHMec (pH 6.0) was added to the assay
buffer and fluorescence was measured in triplicate, at one-minute intervals over
a 30 minutes period, at an excitation of 360 nm and an emission of 465 nm.

Live-cell proteolysis assay. Proteolytic cleavage of DQ-collagen IV by
live IBC cells was imaged in real time and quantified, as previously described
(Jedeszko et al., 2008; Sameni et al., 2009). Briefly, IBC cells (2.5 x 104) were
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seeded on round glass coverslips coated with rBM containing 25 mg/ml DQcollagen IV substrate and incubated at 37 °C for 40 minutes to allow for cell
attachment. Complete media containing 2% rBM was then added to the cultures
and grown for 24 to 48 hours. Live cells were pretreated with Hoechst 33342
nucleic acid stain and imaged with a Zeiss LSM 510 META NLO confocal
microscope, equipped with an incubator (37 °C and 5% CO2) surrounding the
microscope stage, using a 40X Plan neofluar (N.A., 0.7) objective. DQ-collagen
IV cleavage products were observed as green fluorescence (Figure 2.3). Where
specified, the assay was performed in the presence of 10 mM CA074, a highly
selective cathepsin B inhibitor (Murata et al., 1991).

Invasion assay.

Cell culture inserts [8.0 µm transparent PET

membranes], were coated with 2 mg/ml rBM and incubated in a 24-well plate at
room temperature to permit rBM solidification. Complete media, the stimulant for
invasion, was added to the bottom of each well. SUM149 cells (5.0 x 104) in
serum-free media were seeded onto the rBM-coated inserts and incubated for 24
h at 37 °C in the presence of DMSO (vehicle control) or 10 µM CA074. Cells that
had not invaded were removed with a cotton swab. Cells that had invaded were
fixed with 3.7% formaldehyde, stained with DAPI and imaged at 20X
magnification with a Zeiss Axiophot conventional epifluorescent microscope. Ten
random microscopic fields per filter were analyzed. The number of cells that
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Figure 2.3. Cartoon depicting imaging of live cell proteolysis by confocal
microscopy. IBC cells are grown in rBM containing DQ-collagen IV. Using a
water-immersion dipping objective, optical sections as depicted by the gray
rectangles are acquired throughout the entire volume of the 3D cellular
structures.
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invaded was assessed by counting nuclei with MetaMorph™ image analysis
software (Molecular Devices, Sunnyvile, CA).

Immunocytochemical staining. Intracellular co-staining was performed
at room temperature on 2D (permeabilized with 0.1 % saponin) and 3D cultures
(permeabilized with 0.2% Triton X-100). In our experience, Triton X-100, a mild
detergent, is better than saponin for permeabilizing cells grown in 3D cultures.
The cultures were fixed with 3.7% formaldehyde and incubated with the following
primary antibodies diluted in 0.2% Triton X-100/PBS: rabbit anti-caveolin-1
(1:50), mouse anti-uPA (1:25), and mouse anti-uPAR (1:12.5).

Secondary

antibodies [donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa
Fluor 555] were diluted (1:5000) in 0.2% Triton X-100/PBS plus 5% normal
donkey serum. All immunocytochemical staining was imaged on a Zeiss LSM
510 META NLO confocal microscope using either a 100X oil Plan neofluar (N.A.,
1.3) objective (2D cultures) or 40X Plan apofluar (N.A., 0.7) objective (3D
cultures).

Immunohistochemical (IHC) staining of patient samples. Institutional
review board approval from Ain Shams University ethics committee and the
National Cancer Institute, Cairo University along with patient consent forms were
obtained for the purpose of patient enrollment in this study. Inclusion criteria for
patients included clinical, mammographic, ultrasound and pathological diagnosis
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according to the American Joint Committee on Cancer T4 d designation for IBC
(Dawood et al., 2011). Pre-treated formalin fixed paraffin embedded IBC (n = 23)
and non-IBC (stage II-III, n = 27) patient tissue samples were subjected to IHC
analysis (Nouh et al., 2011). Briefly, tissue sections were incubated for one hour
at room temperature with either monoclonal anti-caveolin-1 (1:150) or polyclonal
anti-cathepsin B (1:500) primary antibodies. A second incubation was performed
with HRP rabbit/mouse [EnVision + Dual Link System-HRP (DAB +)] for 45
minutes. Nuclei were counterstained with hematoxylin, sections were mounted
with Permount® and imaged with an Olympus, CX41 light microscope. Patient’s
pathological evaluation, IHC and scoring analysis were done in collaboration with
a group at Cairo University. We performed the statistical analysis for this study.

MTT proliferation assay. IBC cells were seeded (5,000 per well) in 96well plates and cultured overnight. On day one, cells were treated with 3 µM
lovastatin or vehicle (DMSO) containing 200 µl of growth media and cultured for
24, 48 and 72 h. Fifty microliters of MTT stock solution (5 mg/ml) was added to
each well and incubated for 3 h at 37 °C allowing the production of formazan by
living cells. The media was subsequently removed and 150 µl of DMSO was
added to each well and plates were placed on a shaker to dissolve the formazan
for 40 minutes at room temperature.

Absorbance values were measured in

triplicate at a 485 nm wavelength using a SpectraFluor Plus (Teccan, Salzburg,
Austria).
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Filipin III staining. Cells grown in monolayer on round glass coverslips
and treated for 24 h with 3 µM lovastatin or vehicle were washed 3 times with
PBS. Cells were fixed with 3.7% formaldehyde solution for 15 minutes at room
temperature. After washing, the fixed cells were incubated with Filipin III (stock
solution of 5 mg/ml diluted 1:150 in 4% bovine serum albumin/PBS) for 2 hours.
Stained cells were imaged on a Zeiss LSM 510 META NLO confocal microscope
using a 63X oil Plan neofluar (N.A., 1.3) objective.

Lentiviral Transduction of SUM149 cells.

Knockdown of caveolin-1

gene expression was carried out using the OpenBiosystems TRIPZ shRNAmir
Lentiviral Packaging system.

For lentivirus production, HEK293T (Open

Biosystems) cells were cultured in Dulbecco’s modified Eagles medium
containing 10% FBS without antibiotics in 35-mm dishes to 100% confluence.
The cells were then transfected with 5.7 µg of TransLenti Viral Packaging Mix
(pTLA1-Pak, pTLA1-Enz, pTLA1-Env, PTLA1-Rev and pTLA1-TOFF) and 1.8 µg
of each pTRIPZ CAV1 shRNA transfer vector with 37.5 µg of Arrest-In
transfection reagent. HEK293T cells were incubated for 6 hours at 37 °C and 5%
CO2 and the medium was changed to fresh culture medium without antibiotics
and placed in an incubator set at 32 °C and 5% CO2 for 24 hours to produce
viruses. Subsequently the viral broth was harvested and centrifuged at 1000 rpm
for 5 minutes. SUM149 cells (25,000 per well) were seeded in a 12-well plate,
treated with 6 µg/ml polybrene and infected with virus collected from HEK293T
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cells 24, 48 and 72 h post-transfection for 3 rounds of infection. Media was then
changed to complete growth medium of SUM149 cells containing 1 µg/ml
puromycin and 500 ng/ml doxycycline.

Statistical Analysis. A two-tailed, assuming equal variance, Student’s ttest was executed to determine the statistical significance of differences in live
cell proteolysis and invasion assays. P values for the relationship between
cathepsin B expressing breast carcinoma cells, of both IBC and non-IBC, and
caveolin-1 protein expression were assessed with a chi-square test.
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CHAPTER 3
RESULTS

Caveolin-1, β 1-integrin and uPAR expression are higher in SUM149
than in SUM190 cells. Caveolin-1 and β1-integrin form a trimeric complex with
uPAR within caveolae (Schwab et al., 2001), a complex that mediates cell
adhesion and migration. Therefore, we compared expression of caveolin-1 and
β1-integrin in SUM149 and SUM190 cells. There was a striking dissimilarity in
levels of the two proteins (Figure 3.1A), The cell surface receptor for uPA is
uPAR (Vassalli et al., 1985; Cubellis et al., 1986), a GPI-anchored membrane
glycoprotein that has been localized to caveolae in a wide variety of cells (Wei et
al., 1999; Schwab et al., 2001; Cavallo-Medved et al., 2005). We found that
SUM149 cells expressed more receptor than did SUM190 cells (Figure 3.1A),
paralleling the difference in expression of caveolin-1 and β1-integrin. These data
suggest that pericellular proteolysis by the two cell lines may not be the same
due to the observed differences in cav-1, uPAR and β1-integrin expression and
thus the potential to localize pro-uPA and a caveolae-associated protease known
to activate pro-uPA, i.e., cathepsin B, at the cell surface.

Cathepsin B and uPA expression and secretion are similar in
SUM149 and SUM190 cells. Cathepsin B has been linked to both pericellular
and intracellular proteolysis in breast cancer cells (Sameni et al., 2000). Our
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Figure 3.1. Expression of cathepsin B, uPA, uPAR, β1-integrin and
caveolin-1 in SUM149 and SUM190 IBC cells. Duplicate samples of cell
lysates (intracellular) and conditioned media (secreted) from 2D cultures of
SUM149 and SUM190 cells were resolved by SDS-PAGE. Proteins were
transferred to a nitrocellulose membrane and immunoblotted with (A) anti-E
cadherin, anti-uPAR, anti-β1-integrin, anti-caveolin-1 (cav-1) antibodies; (B) antiβ-tubulin antibody as a loading control; (C) an anti-cathepsin B (CTSB) antibody
[bands represent proform (43 kDa), intermediate (38 kDa), single chain mature
(31 kDa), and heavy chain of double chain mature (25/26 kDa) cathepsin B] and
(D) an anti-uPA antibody.
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previous in vitro findings demonstrate that monocytes, an inflammatory
component associated with IBC, stimulate the invasive potential and degradation
of ECM proteins by SUM149 IBC cells (Mohamed et al., 2008). These results
correlate with increased cathepsin B expression and activity in the SUM149 cells.
Recent in vivo studies have also identified cathepsin B as a potential prognostic
marker for IBC (Nouh et al., 2011).

Here we examined two IBC cell lines,

SUM149 and SUM190, for expression of cathepsin B protein. We found that the
two cell lines express comparable levels of the mature single chain (31 kDa) and
double chain (25/26 kDa heavy chain + 5 kDa light chain) forms of cathepsin B in
cell lysates and secrete comparable levels of procathepsin B (43 kDa) into the
media (Figure 3.1C). A 38 kDa intermediate form of the enzyme was present
only in lysates of the SUM149 cells and mature double chain cathepsin B was
secreted only from SUM190 cells (Figure 3.1C); these differences between the
two cell lines are likely due to variations in the extent of processing of the
proenzyme into the various mature forms. We have observed similar differences
in a variety of human tumor tissues (Moin et al., 1992). Since cathepsin B
activates both soluble and cell surface bound pro-uPA (Kobayashi et al., 1991;
Kobayashi et al., 1992; Kobayashi et al., 1993; Guo et al., 2002), we also
compared the expression of uPA in the two IBC cell lines.

Both expressed

similar levels of intracellular pro-uPA; however, secretion of pro-uPA from the
SUM149 cell line was slightly higher (Figure 3.1D).
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IBC cells express E-cadherin. Normal epithelium is highly organized
and exhibits polarity due largely to E-cadherin-mediated cell:cell interactions
called adherens junctions. Deregulation of E-cadherin is a criterion for epithelialmesenchymal transition (EMT), which often accompanies malignant initiation and
progression (Hirohashi, 1998).

Inactivation of adherens junctions in human

cancer is mediated by genetic modification of adherens associated proteins, e.g.,
E-cadherin and catenins (Oda et al., 1994; Oyama et al., 1994), decreased
expression of E-cadherin (Birchmeier and Behrens, 1994) and aberrant
phosphorylation of β-catenin resulting in activation of cancer promoting signaling
pathways (Schmalhofer et al., 2009).

In addition, E-cadherin ectodomain

shedding by proteases is an alternative mechanism of E-cadherin loss of
function.

For example, cathepsin B is capable of cleaving the extracellular

domain of E-cadherin in vitro and in vivo [Roshy, doctoral thesis and (Gocheva et
al., 2006)]. Generally, downregulation or complete loss of E-cadherin expression
correlates with breast cancer that is invasive, higher grade and metastatic (Berx
and Van Roy, 2001; Vincent-Salomon and Thiery, 2003). Elevated levels of Ecadherin are strongly associated with IBC (Kleer et al., 2001).

In contrast,

invasive ductal and lobular carcinomas exhibit significantly reduced expression of
E-cadherin (Moll et al., 1993). Kleer and colleagues suggest that expression of
E-cadherin may facilitate the formation of IBC tumor emboli after intravasation
into lymphatic vessels in vivo. As expected, we found that both IBC cell lines
expressed E-cadherin (Figure 3.1).
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SUM149 and SUM190 cells exhibit different patterns of proteolysis of
type IV collagen. We used a functional live-cell proteolysis assay to assess in
real time degradation of DQ-collagen IV by SUM149 and SUM190 cells. DQcollagen IV cleavage products (green fluorescence) were present in cultures of
both cell lines; however, there were distinct differences in localization of the
fluorescent cleavage products (Figure 3.2).

Cleavage products were found

adjacent to the external cell surface of the SUM149 cells, i.e., pericellularly. In
contrast, in the SUM190 cells a distinct punctate fluorescence pattern was
present intracellularly, consistent with the cleavage products being in vesicles.
This may reflect proteolysis that occurs either intracellularly in the vesicles or
extracellularly with the degradation fragments taken up into the vesicular
compartment by endocytosis.

uPA and uPAR colocalize in caveolae-enriched fractions of SUM149
cells. Our laboratory utilizes two methods for purification of caveolae-enriched
membranes, a non-detergent and a detergent based protocol. These methods
are employed based on the biochemical properties of caveolae: they have a light
buoyant density and are resistant to detergent solubilization. Since non-caveolae
lipid rafts have similar characteristics, there is controversy over purification
methods, however the sodium carbonate method is considered preferable (Song
et al., 1996).

Since expression levels of caveolin-1 and uPAR were high in

SUM149 cells and we have previously shown that uPA and uPAR colocalize in
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Figure 3.2. Live-cell proteolysis assay revealed disparate proteolytic
patterns in 3D cultures of SUM149 and SUM190 cells. SUM149 and SUM190
cells were seeded onto glass-coverslips coated with rBM containing DQ-collagen
IV. Following overnight incubation at 37 °C, cells and DQ-collagen IV cleavage
products (green) were imaged using confocal microscopy (see Materials and
Methods). Live SUM149 and SUM190 cells grown in 3D degraded DQ-collagen
IV pericellularly (arrowhead) and predominantly intracellularly (arrow),
respectively. Confocal Z stack images were reconstructed in 3D utilizing
Volocity™ software (PerkinElmer, Waltham, MA). Representative merged
images of DIC and green channels of the equatorial plane (middle) and two
planes equidistant, 20 µm, from the equatorial plane (top and bottom) are also
shown. Bar, 20 µm.

	
  

	
  

46

caveolar fractions of colorectal carcinoma cells (Cavallo-Medved et al., 2005), we
isolated caveolae-enriched fractions from SUM149 cells. We used a method that
employs a sodium carbonate buffer for cell lysis followed by subcellular
fractionation in a sucrose density gradient (Cavallo-Medved et al., 2009).
Analysis of caveolae-enriched fractions (i.e., fractions in which caveolin-1 was
primarily distributed) revealed that uPA and its receptor uPAR were both present
in these fractions (Figure 3.3A-B). This was observed for SUM149 cells grown
either as 2D or 3D cultures.

For cell fractionation studies, sufficient starting

material is more readily obtained from 2D cultures.

We prefer, however, to

analyze 3D cultures as they more closely resemble the in vivo phenotype
(Debnath and Brugge, 2005) and have been shown to be predictive of drug
responses in vivo (Weigelt and Bissell, 2008; Li et al., 2010). In agreement with
our fractionation studies, immunostaining of 2D (Figure 3.3C) and 3D (Figure
3.3D) cultures of SUM149 cells showed that uPA and uPAR colocalized with
caveolin-1, consistent with a role for caveolin-1 in the distribution of these
proteins to the cell surface.

Active cathepsin B is present in caveolae-enriched fractions of
SUM149 cells.

We have previously shown, using both detergent and non-

detergent methods, that cathepsin B localizes to caveolae-enriched fractions of
colon carcinoma and endothelial cells (Cavallo-Medved et al., 2003; CavalloMedved et al., 2005; Cavallo-Medved et al., 2009). Cathepsin B is denatured
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Figure 3.3. uPA and uPAR codistributed with caveolin-1 in subcellular
fractions of SUM149 cells. Isolation of caveolae from SUM149 cells grown in
2D (A) or in 3D culture (B) was performed using a non-detergent method as
described in Materials and Methods. Equal-volume aliquots of fractions 3-11
were analyzed by SDS-PAGE and immunoblotted with antibodies against uPA,
uPAR or caveolin-1. Merged DIC and fluorescent images are representative
images of SUM149 2D (C) or 3D (D) cultures immunostained for caveolin-1
(green) and uPA (red) or uPAR (red). Colocalization of the two proteins appears
yellow (arrows). Confocal microscopy was performed as described in Materials
and Methods. Bar, 10 µm for 2D cultures; 20 µm for 3D cultures.
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and thus is inactive in the non-detergent based method as the cells are lysed in
sodium carbonate buffer at pH 11. Therefore, to further assess localization of
cathepsin B to caveolae-enriched fractions of SUM149 3D cultures, we utilized a
detergent-based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components. Since caveolae are insoluble in 1% Triton
X-100, the TI fraction contains caveolae and associated proteins and the TS
fraction contains proteins from cellular components that are solubilized by the
detergent including lysosomes. As expected more caveolin-1 was observed in
the TI fraction than the TS fraction (Figure 3.4A).

Caveolin-1 subcellular

localization is not exclusive to caveolae, but is also present in the endoplasmic
reticulum, Golgi and cytosolic where it is presumed to complex with chaperones
or embedded in lipoprotein-like particles (Liu et al., 2002a). Mature forms of
cathepsin B were present in the TI fractions (Figure 3.4A). Substantially higher
levels of mature cathepsin B were present in the TS fractions containing
lysosomes, the predominant subcellular localization of cathepsin B. Cathepsin B
activity was observed in both TS and TI fractions (Figure 3.4B), at levels
comparable to the levels of mature cathepsin B detected by immunoblotting
(Figure 3.4A). The enzymatic activity in the isolated TS and TI fractions was
completely abrogated by CA074, a highly selective inhibitor for cathepsin B
(Murata et al., 1991). The presence of cathepsin B activity in the TI fractions
might be consistent with a functional role for cathepsin B at the cell surface. We
showed that uPA and uPAR colocalize to caveolae-enriched fractions using a
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Figure 3.4. Active cathepsin B is present in caveolae-enriched fractions of
SUM149 3D cultures. Caveolae from SUM149 3D cultures were isolated by a
detergent-based method, as described in Materials and Methods, that separate
Triton X-100-soluble (TS; non-caveolae) from Triton X-100–insoluble (TI;
caveolae-enriched) cellular fractions. (A) Equal volume aliquots of each fraction
were analyzed by SDS-PAGE and immunoblotted with antibodies against
cathepsin B or caveolin-1. (B) TS and TI fractions were assayed for enzymatic
activity against the synthetic cathepsin B substrate Z-Arg-Arg-NHMec.
Cathepsin B activity in both TS and TI fractions was inhibited by 10 µM CA074.
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non-detergent based sucrose fractionation method (Figure 3.3A-B) and obtained
similar results by the detergent based method as well (Figure 3.5). In addition,
we also observed E-cadherin and β1-integrin localized to TI fractions (Figure
3.5).
Our laboratory identified p11, the light chain of the annexin II tetramer, as
a binding partner for procathepsin B in vitro (Mai et al., 2000). Procathepsin B
via its interaction with the light chain of the annexin II tetramer is bound to the
surface of tumor cells. Cathepsin B, p11, and p36 have all been identified in
caveolae-enriched membrane fractions of the human colon carcinoma cell line
HCT 116 (Cavallo-Medved et al., 2003). Using SUM149 cells, we were also able
to show that p36 and p11, the cathepsin B binding partner, localized to caveolaeenriched fractions in these cells (Figure 3.5).

Inhibition of cathepsin B reduces type IV collagen degradation and
invasion by IBC cells. The live-cell proteolysis assays indicated that SUM149
cells degrade DQ-collagen IV pericellularly. Our subcellular fractionation and
enzymatic assays indicated that active cathepsin B is associated with caveolaeenriched fractions and therefore on the surface of SUM149 cells.

Thus, we

examined whether inhibiting cathepsin B would reduce pericellular degradation of
DQ-collagen IV.

For these cell-based assays, we used CA074, the highly

selective cathepsin B inhibitor that is cell-impermeant (Murata et al., 1991) and
thus would only reduce cathepsin B activity outside the SUM149 cells. We used
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Figure 3.5. E-cadherin, β1-integrin, uPA, uPAR, p36 and p11 are localized
to caveolae-enriched fractions of SUM149 3D cultures. Caveolae enriched
fractions were isolated by a detergent based method that separates Triton X-100soluble (TS) from –insoluble (TI) membrane components. TS indicates noncaveolae fractions and TI indicates caveolae-enriched fractions. Equal volumes
of each fraction were analyzed by SDS-PAGE and immunoblotted with anti-Ecadherin, anti-β1-integrin, anti-uPA, anti-uPAR, anti-caveolin-1, anti-p36, anti-p11
and anti-transferrin receptor (TfR) antibodies. TfR is a negative control as it is
not associated with lipid rafts.
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our previously established methods to quantify degradation of DQ-collagen IV on
a per cell basis throughout the entire volume of SUM149 3D cultures (Jedeszko
et al., 2008). We demonstrated that CA074 significantly attenuated degradation
of DQ-collagen IV (Figure 3.6) and invasion (Figure 3.7), suggesting that
cathepsin B contributes to pericellular degradation and invasion by SUM149
cells.

Cathepsin B and caveolin-1 are co-expressed in IBC tissues in vivo.
To determine whether there is an association between cathepsin B and caveolin1 in vivo, we immunostained paraffin-embedded tissue samples from IBC and
non-IBC patients for cathepsin B and caveolin-1.

IBC patients in this study

ranged in age from 29 to 60 years (mean ± SD = 41 ± 8); non-IBC patients
ranged in age from 33 to 67 years (mean ± SD = 50 ± 9). Tumor grade analysis
revealed that 65% and 78% of the IBC and non-IBC samples, respectively, were
grade I or II and 35% and 22% of the IBC and non-IBC samples, respectively,
were grade III. For further clinical and pathological characterization of the IBC
and non-IBC samples, see Nouh et al. (Nouh et al., 2011). In the IBC tissues, we
observed strong expression of cathepsin B in tumor cells and in tumor emboli
within dermal lymphatics and moderate expression in stromal cells (Figure 3.8A
and B). There was heterogeneous staining for caveolin-1 in tumor emboli (Figure
3.8C). Endothelial cells of dermal lymphatics containing tumor emboli stained
strongly for caveolin-1, consistent with the known high levels of caveolae in

	
  

	
  

53

	
  

	
  

54

Figure 3.6. Inhibition of cathepsin B activity modestly, but significantly,
reduced degradation of DQ-collagen IV by SUM149 3D cultures. SUM149
cells were grown as 3D rBM overlay cultures containing DQ-collagen IV in the
presence of either DMSO (control) or 10 µM CA074. Confocal Z stack images
were captured and used to generate 3D reconstructions. (A) Representative 3D
reconstructions of DQ-collagen IV degradation products (green), SUM149 nuclei
(stained with Hoechst 33342, blue). (B) Corresponding intensity map (red being
most intense and blue least intense) of DQ-collagen IV degradation products and
corresponding DIC images (insets). Magnification, 40X. (C) Quantification of
proteolysis in the entire volume of three-dimensional structures measured as the
average integrated intensity of fluorescence per cell and expressed as percent
control. Results from three independent experiments are presented as mean ±
SD; *, P< 0.02.
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Figure 3.7.
Inhibition of cathepsin B activity significantly reduces
invasiveness of SUM149 cells. SUM149 cells were subjected to transwell
invasion assays in the presence of DMSO (vehicle control) or 10 µM CA074. (A)
Cartoon representing setup of invasion assay. (B) Images are SUM149 cells that
have invaded through rBM-coated filters; bar, 150 µm. (C) Quantification of
invaded cells was performed by counting the number of nuclei from 10 fields of
view per filter (using Metamorph software) and expressed as percent control.
Results from three independent experiments are presented as mean ± SD; *, P<
0.05.
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Figure 3.8. Immunohistochemical staining for cathepsin B and caveolin-1
in paraffin sections of IBC tissues. Diffuse cytoplasmic staining for cathepsin
B is present in tumor and stromal cells (A) and tumor emboli (B); magnification,
40x. (C) Caveolin-1 staining is present in tumor emboli (arrow) within dermal
lymphatics and on the surface of dermal lymphatic endothelial cells (arrowhead);
magnification: left panel, 10x and right panel, 40x.
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endothelial cells (Couet et al., 2001).

Furthermore, there was a difference

between IBC and non-IBC carcinoma cells in regard to co-expression of
cathepsin B and caveolin-1. Seventy percent of IBC tumor cells that express
cathepsin B (score of ++ or +++) also expressed caveolin-1 (score of ++ or +++),
whereas only 19% of non-IBC tumor cells showed this co-expression (P = 0.001;
Table 3.1).

Downregulation of caveolin-1 expression in IBC cells.

We

hypothesize that downregulation of caveolin-1 will disrupt caveolae, decrease the
cell surface association of cathepsin B and also reduce both invasion and
degradation of extracellular matrix (ECM).

The role of caveolae and their

structural protein caveolin-1 in breast cancer and other cancers is controversial.
Some studies, both in vitro and in vivo, conclude that caveolin-1 functions as a
tumor suppressor whereas others strongly support an oncogenic and
prometastatic function for caveolin-1 [for review, see (Goetz et al., 2008)]. To
reconcile these contradictory findings, Lloyd and Hardin (2011) have proposed a
model in which the role played by caveolin-1 is dependent on both stage of
disease and tumor type (Lloyd and Hardin, 2011). Lisanti and colleagues have
suggested at early stages of breast cancer and in some ductal carcinomas of the
breast, caveolin-1 is a tumor suppressor (Williams and Lisanti, 2005). On the
other hand, in IBC, caveolin-1 is upregulated and promotes aggressiveness of
these

tumors

(Perou

et

al.,

2000;

	
  

Pinilla

et

al.,

2006).
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Table 3.1. Co-expression of caveolin-1 and cathepsin B in carcinoma cells
of IBC versus non-IBC patient tissues. Immunohistochemical scores of 0 and
+ were considered negative and scores of ++ and +++ were considered positive.
Data presented as number of patients (%). Chi-square = 11.3 (degrees of
freedom = 1).
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High expression of caveolin-1 is a characteristic of triple-negative and other
basal-like breast cancers (Elsheikh et al., 2008). Triple-negative breast cancer
(TNBC) refers to breast cancers that do not express estrogen receptor (ER),
progesterone receptor (PR) and Her2/neu. In addition to increased caveolin-1,
absence of both ER and PR has been reported to be higher in IBC than non-IBC
patient samples (Nguyen et al., 2006); hormone receptor negative breast cancers
are known to have a worse prognosis.
To test whether caveolae are a functional part of the IBC aggressive
phenotype, our experimental approach was to downregulate expression of
caveolin-1 in the SUM149 IBC cell line.

Caveolin-1 is essential to caveolae

biogenesis (Drab et al., 2001; Razani et al., 2001). We predict that caveolin-1
knockdown in IBC cells will result in decreased formation of caveolae and
decrease cathepsin B localization at the cell surface. Knockdown of caveolin-1 in
the SUM149 cells was carried out using the OpenBiosystems TRIPZ shRNAmir
lentiviral packaging system. We chose lentiviral transduction due to the high
efficiency and stability of this technique (Stegmeier et al., 2005; Matrai et al.,
2010).

A feature of the OpenBiosystems TRIPZ system is the Tet-inducible

promoter that regulates expression of the shRNAmir (Figure 3.9). Therefore,
knockdown is inducible in the presence of doxycycline, the tetracycline response
element agonist. In addition, the marker TurboRFP tracks expression of the
shRNAmirs, (control and experimental).

In the absence of doxycycline the

system is turned off thus allowing for an internal control. OpenBiosystems also
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Figure 3.9. Map of TRIPZ plasmid illustrating vector elements: Tet-inducible
promoter (TRE) for regulating expression of knockdown; TurboRFP marker
(tRFP) to track inducible shRNAmir expression.
http://www.openbiosystems.com/RNAi/shRNAmirLibraries/TRIPZlentiviralinducibl
eshR/
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offers a GIPZ Lentiviral shRNAmir system utilizing TurboGFP tracking shRNAmir
expression. This system is not compatible withour live cell proteolysis assay
given that DQ-collagen IV degradation products fluoresce green upon proteolytic
cleavage. For this reason we chose to utilize the TRIPZ rather than the GIPZ
system.
Using six pTRIPZ constructs specific to caveolin-1, we knocked-down the
expression of caveolin-1 by transducing SUM149 cells with lentivirus. Figure
3.10 lists the sequences of each clone ID and the targeting site within the
caveolin-1 mRNA.

To produce the lentivirus, the HEK293T cells were

transfected with each pTRIPZ construct and TransLenti viral packaging mix using
the Arrest-In transfection reagent. The viral broth of the HEK293T cultures was
harvested and used to infect the SUM149 cells.

After three rounds of viral

infection, transduced SUM149 cells were grown in media containing 1 µg/ml
puromycin to selectively kill any non-infected cells. A one µg/ml concentration of
puromycin for selection of SUM149 cells post-lentiviral transduction has been
previously reported (Baillo et al., 2011). To confirm that the 1 µg/ml puromycin
concentration was appropriate for selection in our hands, we monitored the
growth of SUM149 cells in puromycin concentrations ranging from 0 – 5 µg/ml.
Within 4 days, the 1 µg/ml concentration killed 100% of the cells, verifying that
this

concentration

was

appropriate

for

selection

of

SUM149

cells.

Concentrations of puromycin below 1 µg/ml did not kill all cells, whereas
concentrations above 1 µg/ml were toxic within 1 to 2 days.
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Figure 3.10. shRNA target gene set for caveolin-1 gene. (A) Table of the 6
clone IDs and their respective sense and anti-sense sequences. (B) The coding
sequence of the caveolin-1 gene. The clones are highlighted or underlined
indicating their target site within the mRNA of caveolin-1.
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Of the six constructs tested, two induced the greatest levels of caveolin-1
knockdown. To investigate the effect of shRNAmir on the protein expression of
caveolin-1 in the transduced SUM149 cells, we performed immunoblot analysis
of cellular lysates of knockdown SUM149 cells ± doxycycline and of the parental
SUM149 cells (Figure 3.11A).

Immunoblotting showed a large decrease in

caveolin-1 protein levels in two clones: C8 and F2. Densitometric analysis of the
protein bands revealed that when the shRNAmir expression is turned on (i.e., +
doxycycline), caveolin-1 protein expression was decreased approximately 40% in
clone C8 and 95% in clone F2 (Figure 3.11B). As a result of these findings, all
future experiments were performed with clones C8 and F2 ± doxycycline. As a
negative control, we also transduced SUM149 cells with a non-silencing-TRIPZ
lentiviral shRNAmir control that does not target any mRNA sequence in the
mammalian genome.

Knockdown of caveolin-1 does not affect morphology of IBC cells.
As early as 1976, Rohlich and Allison described how the pattern of membraneassociated vesicles, now known to be caveolae, depended on intact microtubule
bundles (Rohlich and Allison, 1976). Later studies demonstrated that the cellular
distribution and dynamics of caveolae require an intact cytoskeleton (Parton et
al., 1994) and that actin is detected in caveolae-enriched microdomains (Lisanti
et al., 1994; Smart et al., 1995).

Caveolae form a bridge between the

extracellular matrix and the cytoplasm. For example, reducing expression of
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Figure 3.11. Caveolin-1 knockdown in SUM149 cells. (A) SUM149 cells
stably infected with caveolin-1 shRNA lentiviral expression constructs were
grown on plastic in either the presence or absence of doxycycline. P = parental
SUM149. Cell lysate was harvested, separated by 12% SDS-PAGE under
reducing conditions and transferred to nitrocellulose. Membranes were blotted
for antibodies against caveolin-1 and β-tubulin as a loading control. (B)
Quantification of densitometric analysis of caveolin-1 signal. Red bar indicates
the decrease in caveolin-1 protein level for each clone.
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caveolin-1 by an antisense approach disrupts β-1 integrin signaling leading to
reduced focal adhesions, phosphorylation of focal adhesion kinase and cell
adhesion (Wei et al., 1999). To test the effect of caveolin-1 knockdown on the
morphology of IBC cells, we cultured control and knockdown populations in 3D
rBM overlay cultures. Parental SUM149 cells grown in three-dimensional rBM
overlay cultures form spheroid-like multicellular structures (Mohamed et al.,
2008). Here, a single cell suspension of 25,000 transduced SUM149 cells was
seeded onto round glass coverslips coated with solidified rBM. The cells were
allowed to adhere to the rBM for 45 minutes. Growth medium containing 2% rBM
was then overlaid onto the cultures.

After 48 hours in culture we assessed

morphology, in 3 independent experiments by confocal microscopy by examining
a tile of 12 fields of vew of cells grown in 3D. With regard to structure complexity
an shape, there were no obvious differences of the 3D structures when control
shRNAmir cells and knockdown clones were cultured in either the presence or
absence of doxycycline (Figure 3.12). These data suggest that the absence of
caveolin-1 does not affect the morphology of IBC cells.

Caveolin-1 knockdown does not affect proliferation of SUM149 cells.
Caveolin-1 negatively regulates cell proliferation. For example, serum starvation
of NIH 3T3 cells increases endogenous levels of caveolin-1 expression and
induces cell cycle arrest in the G0/G1 phase (Galbiati et al., 2001). In addition to
these findings, mouse embryonic fibroblasts isolated from caveolin-1 transgenic
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Figure 3.12. Comparitive growth and morphology of 3D rBM cultures of
caveolin-1 knockdown SUM149 cells. SUM149 cells stably infected with
caveolin-1 shRNA lentiviral expression constructs were grown in 3D rBM culture
either the presence or absence of doxycycline. Cultrex coated glass coverslips
were seeded with 25,000 cells and grown for 2 days. Merged DIC and
fluorescent tile images of the cultures were imaged using confocal microscopy.
Magnification, 40X.
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mice exhibit a p53/p21-mediated reduction in cellular proliferation.

A growth

regulating function of caveolin-1 has also been demonstrated in a panel of nonIBC human breast cancer cell lines (Lee et al., 1998). To evaluate whether
knockdown of caveolin-1 affects proliferation of IBC cells, we performed MTT
assays over a 72 h period. Cultures of control shRNAmir cells, clones C8 and F2
were grown in the presence of 500 ng/ml of doxycycline or absence.
Interestingly knockdown of caveolin-1 expression did not change the proliferation
of IBC cells as measured by the ability of cells to reduce the MTT substrate
(Figure 3.13).

Knockdown SUM149 cells exhibit altered distribution of caveolin-1.
Analysis of whole cell lysates demonstrated that shRNAmir sequences resulted
in decreased caveolin-1 protein (Figure 3.11).

In addition we analyzed the

subcellular localization of caveolin-1 in both control and knockdown populations.
Transduced SUM149 cells were grown in the absence or presence of
doxycycline to induce expression of the shRNAmir. These cultures were then
subjected to the detergent-based method of subcellular fractionation separating
Triton X-100-soluble (TS) from –insoluble (TI) membrane components. Equal
volume aliquots of each fraction were separated by 12% SDS-PAGE under
reducing conditions, transferred to nitrocellulose and probed for caveolin-1. In
comparison to untreated samples (no doxycycline), caveolin-1 protein levels
were clearly reduced in both fractions of clones C8 and F2 treated with

	
  

	
  

69

	
  

	
  

70

Figure 3.13. Knockdown of caveolin-1 does not alter proliferation of IBC
cells as assessed by MTT assays. Control shRNAmir, clone C8 and clone F2
were seeded in 96-well plates (5,000 per well) ± doxycycline. At 24, 48 and 72 h
time points, 50 µl of MTT stock solution was added to each well and incubated at
37°C for 3 hours. Media was removed and 150 µl of DMSO added to each well
dissolving the formazan precipitate. Absorbance values were measured at a
485-nm wavelength.
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doxycycline (Figure 3.14). As expected, no discernable difference was observed
in the control shRNAmir cells ± doxycycline.

Knockdown of caveolin-1 decreases degradation of DQ-collagen IV
by SUM149 3D cultures. We have previously shown that caveolin-1 expression
affects the degradation of collagen type IV (Cavallo-Medved et al., 2005). When
antisense was used as a method to target caveolin-1 expression in human
colorectal carcinoma cells, they degraded less collagen IV than control cells.
Therefore, we investigated whether downregulation of caveolin-1 can affect the
ability of IBC cells to degrade type IV collagen. Using our live-cell proteolysis
assay we demonstrated that cleavage products of type IV collagen were found
adjacent to the external cell surface of parental SUM149 cells (Figure 3.2). We
seeded individual cells of knockdown populations and control shRNAmir cells
onto rBM containing DQ-collagen IV and grew them for 48 hours ± 500 ng/ml
doxycycline. We then imaged DQ-collagen IV degradation in live cultures of IBC
cells using confocal microscopy.

Both caveolin-1 knockdown and control

shRNAmir cells exhibited a pericellular pattern of proteolysis similar to that of the
parental SUM149 cells. Confocal Z stack images were captured throughout the
three-dimensional volume and used to generate 3D reconstructions (Figures
3.15-3.17). Quantitative analysis with Metamorph software revealed that control
shRNAmir cells and clone C8 cultures exhibited no significant difference in the
intensity of degradation products ± doxycycline treatment (Figure 3.18).
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Figure 3.14. Distribution of caveolin-1 to lipid enriched fractions is
decreased in knockdown SUM149 cells. Caveolae-enriched fractions from
transduced SUM149 grown ± 500 ng/ml doxycycline were isolated by a
detergent-based method that separates Triton X-100-soluble (TS) from Triton X100–insoluble (TI) cellular fractions. Equal volumes of each fraction were
analyzed by SDS-PAGE and immunoblotted with antibodies against caveolin-1.
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Figure 3.15. Degradation of DQ-collagen IV by control shRNAmir cells.
Control shRNA mir cells were grown as 3D cultures in rBM containing DQcollagen IV in the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.
Representative 3D reconstructions of DQ-collagen IV degradation products
(green) and corresponding DIC images shown. Magnification, 40X.
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Figure 3.16. Degradation of DQ-collagen IV by caveolin knockdown cells.
Clone C8 cells were grown as 3D cultures in rBM containing DQ-collagen IV in
the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.
Representative 3D reconstructions of DQ-collagen IV degradation products
(green) and corresponding DIC images shown. Magnification, 40X.
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Figure 3.17. Degradation of DQ-collagen IV by caveolin knockdown cells.
Clone F2 cells were grown as 3D cultures in rBM containing DQ-collagen IV in
the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.
Representative 3D reconstructions of DQ-collagen IV degradation products
(green) and corresponding DIC images shown. Magnification, 40X. Bar, 50 µm.
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In contrast, a significant reduction in degradation of DQ-collagen IV by clone F2
cells was observed.

Thus, in the F2 clone cells, when expression of the

caveolin-1 targeting shRNAmir is induced, i.e. + doxycycline, and expression of
caveolin-1 is knocked down, degradation by IBC cells of collagen IV is reduced.

Caveolin-1 knockdown results in reduced invasion by IBC cells. An
abundance of tumor emboli in lymphatic vessels is one pathological feature
distinguishing IBC from non-IBC (Bonnier et al., 1995). Therefore, we studied
the role of caveolin-1 in the invasive phenotype of IBC.

Invasion through

transwell filters coated with rBM is a commonly used assay to test the invasive
capacity of cells in vitro. In these experiments, we seeded equal numbers of
control shRNAmir, clone C8 or clone F2 cells on rBM-coated transwell filters with
or without 500 ng/ml of doxycycline. The cells were incubated with serum free
media and complete media (Ham’s F12 media with 5% FBS) below the rBMcoated transwell filter to stimulate invasion. Following 24 hours rBM and noninvasive cells were removed from the top of filter. The cells that had invaded,
i.e., the cells attached to the bottom of the filter insert, were fixed and stained
using Diff-Quik Stain Set. Filters were cut from the insert, mounted on a slide
and invaded cells were imaged for counting by two independent observers. Only
the clone F2 exhibited a decrease in the number of invaded cells when treated
with 500 ng/ml doxycycline relative to untreated (Figure 3.19).
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Figure 3.18. Knockdown of caveolin-1 decreases degradation of DQcollagen IV by IBC cells. Quantification of proteolysis in the entire volume of
three-dimensional structures measured as the average integrated intensity of
fluorescence was normalized to the number of cells. Results from at least three
independent experiments are presented as mean ± SD; *, P< 0.05.
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Figure 3.19.
Knockdown of caveolin-1 expression decreases the
invasiveness of IBC cells. Transduced SUM149 cells were subjected to
transwell invasion assays in the presence of 500 ng/ml of doxycycline (+ dox) or
untreated (- dox). (A) Images are cells that have invaded through rBM-coated
filters. Magnification, 20X. (B) Quantification of invaded cells was performed by
counting the number of cells that invaded through rBM-coated transwell filters.
Bars represent mean ± SD; n=3.
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Cathepsin B distributes to lipid microdomains in caveolin-1
knockdown IBC cells.

Active cathepsin B localized to caveolae-enriched

microdomains of SUM149 parental cells (Figure 3.4). We also demonstrated that
inhibition of pericellular cathepsin B activity reduced extracellular matrix
degradation and invasion of SUM149 parental cells (Figures 3.6 and 3.7).
Caveolin-1 knockdown studies (Figures 3.15-17) revealed similar decreases in
degradation and invasion by the F2 clone. To determine if caveolin-1 mediates
cell surface localization of cathepsin B, we examined the subcellular distribution
of cathepsin B in control shRNAmir cells and caveolin-1 knockdown populations.
Three-dimensional rBM overlay cultures of control shRNAmir cells and caveolin-1
knockdown cells ± 500 ng/ml of doxycycline were subjected to detergent-based
subcellular fractionation. Interestingly, we observed no change in the distribution
of cathepsin B in caveolin-1 knockdown (doxycycline treated) cells as compared
to untreated cells (Figure 3.20A). As expected, no changes in the distribution of
cathepsin B were observed in control shRNAmir transduced cells ± doxycycline
treatment (Figure 3.20A). The TS and TI fractions of control shRNAmir and
clone F2 were also assayed for cathepsin B activity. We detected no differences
in the activity of cathepsin B in doxycycline treated caveolin-1 knockdown (Figure
3.20C) and control shRNAmir cells (Figure 3.20B). These findings correspond to
those of our immunoblotting studies and suggest that decreased caveolin-1 in the
TI fraction and more specifically in the lipid microdomain fractions of IBC cells
has no effect on the subcellular distribution of cathepsin B. We also investigated
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Figure 3.20. Active cathepsin B is present in caveolae-enriched fractions of
caveolin-1 knockdown SUM149 cells in 3D cultures. Control shRNAmir and
clone F2 3D cultures were subjected to detergent-based cellular fractionation
method, as described in Materials and Methods, that separate Triton X-100soluble (TS; non-caveolae) from Triton X-100–insoluble (TI; caveolae-enriched)
cellular fractions. (A) Equal volume aliquots of each fraction were analyzed by
SDS-PAGE and immunoblotted with antibodies against cathepsin B and
caveolin-1. (B) Equal volume aliquots of (B) control mir and (C) clone F2 TS and
TI fractions were assayed for enzymatic activity against the synthetic cathepsin B
substrate Z-Arg-Arg-NHMec.

	
  

	
  

81

the localization of uPA and other proteins known to be associated with caveolae.
In human colorectal carcinoma cells, we have established that the cell surface
association of cathepsin B, uPA and their binding partners is caveolin-1
dependent (Cavallo-Medved et al., 2005).

We observed no changes in the

distribution to TI fractions of uPA, E-cadherin, β1-integrin, p36 and p11 in control
shRNAmir cells when treated with doxycycline as compared to untreated cells
(Figure 3.21).

In contrast, knockdown caveolin-1 cells exhibited decreased

distribution of uPA to the TI fraction when treated with doxycycline as compared
to untreated cells (Figure 3.22).
Inhibiting cathepsin B activity reduced both type IV collagen degradation
and invasion by IBC cells. Downregulation of caveolin-1 in IBC cells did not
change the distribution of cathepsin B at the cell surface.

Knockdown of

caveolin-1 in clone F2 cells did, however, cause a decrease in both the
degradation of collagen IV and invasion, consistent with a mechanism other than
cathepsin B activity may be responsible for these findings. Signaling pathways
mediated by EGFR have been thoroughly studied especially in TNBC [for review,
see (Foley et al., 2010)].

Overexpression of EGFR and caveolin-1 are

associated with triple negative breast cancers (Pinilla et al., 2006; Rastelli et al.,
2010). This includes SUM149, a triple negative breast cancer cell line that also
expresses EGFR, and in which EGFR localizes to lipid microdomains (Irwin et
al., 2011). To determine if caveolin-1 mediates the association of EGFR with
lipid microdomains, we assessed the subcellular distribution of EGFR in caveolin-
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Figure 3.21. Subcellular distribution of E-cadherin, β1-integrin, uPA, p36
and p11 is unchanged in control shRNAmir transduced IBC cells. Caveolae
enriched fractions were isolated from control shRNAmir cells ± doxycycline by a
detergent based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components. TS indicates non-caveolae fractions and
TI indicates caveolae-enriched fractions. Equal volumes of each fraction were
analyzed by SDS-PAGE and immunoblotted with anti-E-cadherin, anti-β1integrin, anti-uPA, anti-p36, anti-p11 and anti-transferrin receptor (TfR)
antibodies. TfR is a negative control for lipid rafts.
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Figure 3.22. E-cadherin, β1-integrin, uPA, p36 and p11 are present in
caveolae-enriched fractions of caveolin-1 knockdown SUM149 cells in 3D
culture. Caveolae enriched fractions were isolated from clone F2 ± doxycycline
by a detergent based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components. TS indicates non-caveolae fractions and
TI indicates caveolae-enriched fractions. Equal volumes of each fraction were
analyzed by SDS-PAGE and immunoblotted with anti-E-cadherin, anti-β1integrin, anti-uPA, anti-p36, anti-p11 and anti-transferrin receptor (TfR)
antibodies. TfR is a negative control as it is not associated with lipid rafts.
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1 knockdown cells. We observed decreased EGFR in both TS and TI fractions of
clone F2 cells when treated with 500 ng/ml doxycycline (Figure 3.23). These
findings indicate that caveolin-1 may play a role in the expression of EGFR and
mediate its cell surface localization in IBC cells.

Analysis of caveolin-1 expression and cathepsin B localization in a
new IBC cell line. The human cell line MDA-IBC-3 (a kind gift of Dr. Wendy
Woodward developed at The University of Texas MD Anderson Cancer Center,
Texas) was obtained from a patient with IBC and generated from primary breast
cancer cells isolated from pleural effusion fluid (Klopp et al., 2010). The SUM149
and SUM190 are the only commercially available IBC cell lines for in vitro
investigation. Therefore, we thought it important to test our hypothesis with this
additional IBC cell line. To initiate analysis of the new IBC cell line, we compared
the protein expression of cathepsin B and caveolin-1 in three IBC cell lines
(SUM149, SUM190 and MDA-IBC-3) when grown in monolayer cultures on
plastic.

MDA-IBC-3 cells express more cathepsin B protein as assessed by

SDS-PAGE and immunoblotting (Figure 3.24A).

We previously found that

SUM190 does not have detectable caveolin-1 protein and surprisingly neither
does the MDA-IBC-3 cell line (Figure 3.24A).
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Figure 3.23. Knockdown of caveolin-1 decreases the expression and cell
surface localization of EGFR in IBC cells. Control mir and clone F2 3D
cultures were subjected to detergent-based cellular fractionation method, as
described in Materials and Methods, that separate Triton X-100-soluble (TS; noncaveolae) from Triton X-100–insoluble (TI; caveolae-enriched) cellular fractions.
(A) Equal volume aliquots of each fraction were analyzed by SDS-PAGE and
immunoblotted with antibodies against EGFR.
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Figure 3.24. Cathepsin B expression and localization in a new IBC cell line
MDA-IBC-3. (A) IBC cells (SUM149, MDA-IBC-3 and SUM190) grown on plastic
were harvested in lysis buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1% Triton X100, 60 mM octylglucoside) and equally loaded samples separated by 12% SDSPAGE under reducing conditions. Proteins were transferred to nitrocellulose
membrane and immunoblotted with anti-CTSB and anti-caveolin-1 polyclonal
antibodies. The immunoblot for caveolin-1 was overexposed to ensure no
observable caveolin-1 signal was detectable in MDA-IBC-3 and SUM190 lysate.
(B) MDA-IBC-3 cells grown as a monolayer were subjected to subcellular
fractionation on a sucrose gradient. Equal volumes of each fraction were
analyzed by SDS-PAGE and immunoblotted for cathepsin B.
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Cathepsin B localizes to plasma membrane domains other than
caveolae. Caveolin-1 protein expression is essential to caveolae formation (Drab
et al., 2001; Razani et al., 2001). Since caveolin-1 protein was not detected in
both MDA-IBC-3 and SUM190 lysates, we hypothesized that these cells might
not have caveolae. Subcellular fractionation of SUM190 cells showed that
cathepsin B localized to low-density lipid fractions despite the absence of
caveolin-1 (Cavallo-Medved, unpublished data).

We also investigated the

subcellular localization of cathepsin B in MDA-IBC-3 cells. We subjected MDAIBC-3 cells grown in monolayer to the non-detergent based sucrose density
fractionation gradient method. As expected cathepsin B localized to fractions 811, i.e., fractions containing endolysosomes (Figure 3.24B). Cathepsin B also
distributed to a low-density lipid fraction, i.e., fraction 5, containing lipid
microdomains.

These data suggest that cathepsin B may localize to non-

caveolar lipid microdomains in the plasma membrane of MDA-IBC-3 cells.

Treatment of IBC cells with lovastatin: a pharmacological approach
to disrupt lipid microdomains. Statins are a class of drug primarily used in
prevention, monitoring and treatment of cardiovascular disease. Statins prevent
the catalysis of mevalonate by inhibiting the enzymatic activity of HMG-CoA
reductase, an important rate-limiting step in the cholesterol biosynthesis
pathway. Therefore, statins have lipid-lowering activity. Asymmetric distribution
of cholesterol and other lipids in the plasma membrane results in lipid-enriched
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domains or lipid rafts including caveolae (Simons and Ikonen, 1997; Simons and
Toomre, 2000). Caveolae are a specialized and distinct type of lipid raft, which
are highly enriched in and dependent on cholesterol for biosynthesis (Rothberg
et al., 1992).

We hypothesize that cholesterol depletion by statin drugs will

disrupt lipid microdomains, including caveolae. Here we used a statin, lovastatin,
as an alternative approach for testing our hypothesis that cell surface association
of the cysteine protease cathepsin B, the serine proteases of the plasminogen
cascade in caveolae enhances cell surface proteolysis, and ultimately, the
aggressiveness of IBC cells.

Proliferation of IBC cell lines differs in response to lovastatin
treatment. Statins have been reported to reduce proliferation of breast cancer
cells in vitro and in vivo (Campbell et al., 2006). In the study by Campbell et al.,
treatment with multiple statins, including lovastatin, inhibited growth of MDA-231,
SKBr3 and MCF-7 cells. To determine the effects of lovastatin on growth of IBC
cells, we performed MTT assays. Proliferation of SUM149, SUM190 and MDAIBC-3 cells was quantified at 0, 24, 48 and 72 hours in the presence of 3 µM
lovastatin or DMSO (vehicle control) (Figure 3.25). We observed no change in
the proliferation of SUM190 cells at any time point (Figure 3.25B). A small, but
insignificant, decrease in proliferation of SUM149 cells was observed, but only
after treatment for 72 hours (Figure 3.25A).

MDA-IBC-3 cells were most

sensitive to lovastatin in that proliferation was significantly decreased beginning
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Figure 3.25. Lovastatin decreases proliferation of MDA-IBC-3 cells. (A)
SUM149, (B) SUM190, and (C) MDA-IBC-3 cells were seeded in 96-well plates
(5,000 per well) with 3 µM lovastatin or DMSO (vehicle control). At 0, 24, 48 and
72 h time points, 50 µl of MTT stock solution was added to each well and
incubated at 37°C for 3 hours. Media was removed and 150 µl of DMSO added
to each well dissolving the formazan precipitate. Absorbance values were
measured at a 485-nm wavelength with a SpectraFluor Plus plate reader (Tecan,
Salzburg, Austria). Results from three independent experiments are presented
as mean ± SD.
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48 hours after drug treatment (Figure 3.25C). These results indicate that the
three IBC cells do not exhibit the same pattern of lovastatin responsiveness.

Lovastatin treatment of IBC cells decreases cathepsin B expression
and activity.

In models of cardiac hypertrophy and atherosclerosis, statin

treatment has been shown to inhibit the expression and activity of proteases,
including cathepsin B (Kim et al., 2009; Qin et al., 2010). We investigated the
expression of cathepsin B protein in IBC cells following treatment with lovastatin.
At 48, 72 and 96 hours, lysate samples were collected and assayed by SDSPAGE and immunoblotting. We observed no changes in expression of cathepsin
B in the presence of 1 µM lovastatin at any time point (data not shown). Three
µM lovastatin did decrease levels of cathepsin B protein (Figure 3.26A). This
effect of lovastatin treatment was not time-dependent as further decreases did
not occur at 72 and 96 h, as assessed by densitometric analysis of immunoblots
(data not shown). The differences in cathepsin B were most striking at the 48
hour time point (Figure 3.26B).

We also measured intracellular cathepsin B

activity in the lysates of lovastatin treated SUM149 cells. In agreement with the
decreases in the mature (31 and 25/26 kDa) cathepsin B forms observed by
immunoblotting, cathepsin B activity was reduced by treatment with lovastatin
(Figure 3.26C). These findings were not exclusive to SUM149 cells; exposure to
3 µM lovastatin for 48 h reduced cathepsin B activity and protein levels in MDAIBC-3 and modestly in SUM190 (Figure 3.27A-C) cells. The effect of lovastatin
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Figure 3.26. Lovastatin treatment decreased cathepsin B expression and
activity in SUM149 cells. 2D cultures of SUM149 were grown in the presence
of 3 µM lovastatin for 48, 72 or 96 hours. (A) Lysates were equally loaded based
on protein concentration and separated on 12% SDS-PAGE under reducing
conditions. Proteins were transferred to nitrocellulose and immunoblotted with
an anti-cathepsin B polyclonal antibody and anti-β-tubulin monoclonal antibody
as a loading control. (B) Densitometric analysis (48 h exposure to lovastatin) of
cathepsin B signal for the different molecular weight species of cathepsin B
(expressed as AU/mm2). Proform, 45 kDa; intermediate 38 kDa, single chain
mature, 31 kDa; double chain mature, 25/26 kDa. (C) Enzymatic activity assay.
Lovastatin treated and control SUM149 (48 hours) lysate samples were assayed
for cathepsin B activity against the synthetic substrate Z-Arg-Arg-NHMec. Error
bars represent standard deviation of three replicates in one experiment.
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Figure 3.27. Lovastatin treatment decreased cathepsin B expression and
activity in IBC cells. 2D cultures of MDA-IBC-3 and SUM149 cells were grown
in the presence of 3 µM lovastatin for 48 hours. (A) Lysates were equally loaded
based on protein concentration and samples were separated on 12% SDS-PAGE
under reducing conditions. Proteins were transferred to nitrocellulose and
immunoblotted with an anti-cathepsin B polyclonal antibody and anti-β-tubulin
monoclonal antibody as a loading control. (B) MDA-IBC-3 and (C) SUM190
lysate samples were assayed for cathepsin B activity against the synthetic
substrate Z-Arg-Arg-NHMec. Error bars represent standard deviation of three
replicates in one experiment.
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on cathepsin B protein and activity seems a general phenomenon since we
observed similar results in three unrelated IBC cell lines.
Statins have shown promise in inhibiting fibrosis (Trebicka et al., 2010);
proteases of the plasminogen cascade, including uPA, play a principal role in
fibrinolysis. We also investigated if statin treatment can affect expression of uPA.
Treatment with lovastatin reduced the amount of both secreted and intracellular
uPA in SUM149 cells but no change was observed in its receptor uPAR (Figure
3.28).

Treatment with lovastatin decreases cholesterol in IBC cells. The
fluorescent antifungal filipin has a high affinity for cholesterol or sterol molecules
that contain a 3β-hydroxyl group and is commonly used to detect non-esterified
cholesterol/sterols (Gimpl and Gehrig-Burger, 2007). Due to this property, filipin
is widely used as a histochemical stain for cholesterol, e.g., filipin staining of
cholesterol in cellular membranes is used as a diagnostic tool for Niemann-Pick
disease (Ledvinova and Elleder, 1993). To further investigate the lipid lowering
activity of lovastatin in IBC cells, SUM149 cells treated with 3 µM lovastatin or
DMSO for 48 hours were fixed and stained with filipin III.

In comparison to

control cells, we observed decreased staining intensity for filipin III along the
periphery of cells treated with lovastatin (Figure 3.29), indicative of decreases in
total cellular cholesterol. These data provide an indirect indication that treatment
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Figure 3.28. Lovastatin treatment decreases expression and secretion of
uPA in SUM149 cells. Cell lysate (intracellular) and conditioned media
(secreted) samples from 2D cultures of SUM149 treated with 3 µM lovastatin for
48 hours were separated on 12% SDS-PAGE under reducing conditions.
Proteins were transferred to nitrocellulose and immunoblotted with an anti-uPA
antibody, anti-uPAR and an anti-β-tubulin monoclonal antibody as a loading
control.
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Figure 3.29. Lovastatin decreases cholesterol content in SUM149 cells. (A)
Representative fluorescent images of SUM149 treated with 3 µM lovastatin or
DMSO (vehicle control) for 48 hours and stained with filipin III. (B)Intensity of
filipin III staining of SUM149 cells was analyzed with Metamorph software and
represented as arbitrary intensity values (n=20).
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with lovastatin decreased cholesterol in IBC cells and thereby affected lipid
microdomains, including caveolae.

Lovastatin affects caveolin-1 levels in lipid-enriched fractions of
SUM149 cells. Treatment with simvastatin, another member of the statin class of
pharmaceuticals, decreases both cholesterol content and caveolin-1 expression
in lipid fractions of human glioma cells (Wu et al., 2009).

To determine if

lovastatin elicits a similar effect on caveolin-1 in IBC cells, SUM149 cells were
treated with lovastatin for 48 hours and subjected to subcellular fractionation on a
sucrose gradient.

Caveolin-1 primarily distributed to fractions 4-6 in control

(DMSO) cells (Figure 3.30A) in agreement with previous data (Figure 3.3). We
observed a decrease in the distribution of caveolin-1 to these lipid fractions when
SUM149 cells were treated with lovastatin (Figure 3.30A).

We also isolated

caveolae-enriched fractions by a successive detergent based method: TS
represents non-caveolae fractions and TI represents caveolae-enriched fractions.
In the presence of lovastatin we observed decreased caveolin-1 in the TI fraction
and a moderate increase in the TS fraction. This would be consistent with a
change in localization of caveolin-1. In agreement with these data, we observed
decreases in caveolin-1 localization when SUM149 were cells treated with
lovastatin. The staining pattern for caveolin-1 in DMSO (diluent control) treated
cells is along the plasma membrane.

	
  

Following treatment with lovastatin,
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Figure 3.30. Lovastatin decreased caveolin-1 distribution to lipid fractions
of IBC cells. SUM149 cells treated with 3 µM lovastatin or DMSO (vehicle
control) for 48 hours were subjected to both non-detergent sucrose gradient (A)
and detergent based (C) subcellular fractionations. Equal volumes of each
fraction were analyzed by SDS-PAGE and immnoblotted for caveolin-1. (B)
Protein bands were analyzed by densitometry. Graphical representation of
caveolin-1 distribution in the sucrose gradient fractions.
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Figure 3.31. Immunostaining of lovastatin treated SUM149 reveals a
decrease in caveolin-1 along the cell periphery. Immunostaining for caveolin1 (green) was performed on permeabilized SUM149 monolayer cultures treated
with 3 µM lovastatin or DMSO (vehicle control). Nuclei were stained with DAPI
(blue). Confocal images were captured using a Leica TCS SP5 confocal
microscope and 63X oil objective. Bar, 25 µm.
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caveolin-1 staining exhibits a more cytoplasmic pattern with less staining at the
plasma membrane (Figure 3.31).

Mevalonic Acid (MVA) rescues changes in cathepsin B subcellular
distribution and decreases in cathepsin B activity in lovastatin treated IBC
cells. Our knockdown studies revealed that cathepsin B membrane association
is independent of caveolin-1 expression.

However, lovastatin decreased

cathepsin B protein levels, cholesterol content and caveolin-1 association with
lipid fractions of IBC cells.

To determine whether lovastatin affects the

subcellular distribution of cathepsin B, 3D cultures of IBC cells were treated for
48 hours with 3 µM of drug and subjected to subcellular fractionation using the
detergent based method. We also treated the cultures with MVA in the presence
of lovastatin. HMG-CoA reductase, the direct target of statin drugs, catalyzes
production of MVA in the cholesterol biosynthesis pathway. Therefore, we added
exogenous MVA to test if this would rescue the lovastatin-induced phenotype. In
agreement with the data in figure 3.4, cathepsin B was present in both the TS
and TI fractions of SUM149 control (DMSO) cultures (Figure 3.32A). Treatment
with lovastatin decreased the amount of cathepsin B in both the TS and TI
fractions. MVA partially rescued the observed decreases (Figure 3.32A). We
also performed this experiment of MDA-IBC-3 and SUM190 IBC cells. Similar to
our findings in the SUM149 cultures, cathepsin B protein levels were decreased
in both TS and TI fractions of MDA-IBC-3 cells when treated with lovastatin and
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Figure 3.32. Mevalonic acid (MVA) partially rescues lovastatin-induced reduction
of cathepsin B protein and activity in subcellular fractions of SUM149 3D cultures.
SUM149 3D cultures were isolated by a detergent-based method, as described in
Materials and Methods, that separate Triton X-100-soluble (TS) from Triton X-100–
insoluble (TI) cellular fractions. (A) Equal volume aliquots of each fraction were analyzed
by SDS-PAGE and immunoblotted with an antibody against cathepsin B. (B) TS and TI
fractions were assayed for enzymatic activity against the synthetic cathepsin B substrate
Z-Arg-Arg-NHMec. Cathepsin B activity in both TS and TI fractions was inhibited by 3
µM Lovastatin. MVA rescued this phenotype.
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Figure 3.33.
Mevalonate (MVA) partially rescues lovastatin-induced
reduction of cathepsin B protein and activity in subcellular fractions of
MDA-IBC-3 3D cultures. MDA-IBC-3 3D cultures were isolated by a detergentbased method, as described in Materials and Methods, that separate Triton X100-soluble (TS) from Triton X-100–insoluble (TI) cellular fractions. (A) Equal
volume aliquots of each fraction were analyzed by SDS-PAGE and
immunoblotted with an antibody against cathepsin B. (B) TS and TI fractions
were assayed for enzymatic activity against the synthetic cathepsin B substrate
Z-Arg-Arg-NHMec. Cathepsin B activity in both TS and TI fractions was inhibited
by 3 µM Lovastatin. MVA partially rescued this phenotype.
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Figure 3.34. Lovastatin does not affect cathepsin B protein and activity in
subcellular fractions of SUM190 3D cultures. SUM90 3D cultures were
isolated by a detergent-based method, as described in Materials and Methods,
that separate Triton X-100-soluble (TS) from Triton X-100–insoluble (TI) cellular
fractions. (A) Equal volume aliquots of each fraction were analyzed by SDSPAGE and immunoblotted with an antibody against cathepsin B. (B) TS and TI
fractions were assayed for enzymatic activity against the synthetic cathepsin B
substrate Z-Arg-Arg-NHMec. Cathepsin B activity in both TS and TI fractions
was inhibited by 3 µM Lovastatin.
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were modestly rescued by adding back exogenous MVA (Figure 3.33A). The
SUM190 cells exhibited decreased sensitivity to lovastatin treatment in
comparison to SUM149 and MDA-IBC-3 cells. Lovastatin treatment of SUM190
did not elicit the same decreases in cathepsin B protein levels or changes in
subcellular distribution (Figure 3.34A).
Alterations in distribution of cathepsin B were further investigated by
comparing the activity of cathepsin B in both TS and TI fractions of control,
lovastatin treated cells and by adding MVA. We detected cathepsin B activity in
both the TS and TI control fractions of all three IBC cell lines that were
comparable to the levels of mature cathepsin B detected by immunoblotting
(Figures 3.33B, 3.34B and 3.35B). Treatment with lovastatin reduced the activity
of cathepsin B in both fractions of SUM149 and MDA-IBC-3 cultures but not in
the SUM190 cells (Figure 3.34B). Addition of exogenous MVA in the presence of
lovastatin partially restored the activity of cathepsin B in both the TS and TI
fractions of SUM149 and MDA-IBC-3 cultures (Figures 3.32B and 33.3B).

Lovastatin treatment reduces type IV collagen degradation and
invasion by IBC cells.

Our subcellular fractionation and enzymatic assays

indicated that active cathepsin B is associated with TI fractions of IBC cells.
Lovastatin treatment diminished the levels of cathepsin B protein and activity in
TI fractions. In addition, inhibiting cathepsin B activity significantly diminished
degradation of DQ-collagen IV (Figure 3.6) and invasion (Figure 3.7), suggesting
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that cathepsin B contributes to pericellular degradation and invasion by IBC cells.
Therefore, we examined whether treatment with lovastatin would reduce
degradation of DQ-collagen IV and invasion of IBC cells. For these studies, we
used our live cell proteolysis assay to image the degradation of DQ-collagen IV
by SUM149, MDA-IBC-3 and SUM190 cells grown for 48 hours and treated with
3 µM lovastatin or DMSO (vehicle control). Lovastatin significantly decreased the
intensity of pericellular degradation products of DQ-collagen IV surrounding
SUM149 3D structures (Figure 3.35A and B).
When grown in 3D rBM overlay cultures, MDA-IBC-3 cells form
spheroid-like multicellular structures similar to those observed for SUM149 cells,
yet exhibited a different pattern of proteolysis resembling that observed for
SUM190 cells (Figure 3.2). The DQ-collagen IV cleavage products associated
with MDA-IBC-3 structures appeared punctate or intracellular rather than
pericellular (Figure 3.36). In addition, we observed the intensity of degradation
products in MDA-IBC-3 cultures to be less than in SUM149 cultures, indicating
that these cells degraded less collagen IV.

Similar to the SUM149 cells,

lovastatin treatment of MDA-IBC-3 cells changed cathepsin B subcellular
distribution and decreased cathepsin B activity. When the MDA-IBC-3 cells were
treated with lovastatin, degradation of DQ-collagen IV was not affected (Figure
3.36A and B). Degradation of DQ-collagen IV by SUM190 cells also was not
affected by treatment with lovastatin (Figure 3.37A and B).
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Figure 3.35. Lovastatin reduced degradation of DQ-collagen IV by SUM149
3D cultures. SUM149 cells grown in 3D rBM cultures containing DQ-collagen IV
were treated with Lovastatin (3 µM) or DMSO (vehicle control) for 48 hours. (A)
Representative confocal micrographs of the equatorial plane of the DQ-collagen
IV degradation channel (green) and corresponding DIC channel are shown.
Nuclei were stained with Hoechst (blue). Bar, 22 µm. (B) Data are represented as
integrated fluorescence intensity due to proteolysis in the entire volume of 3D
structures and was normalized to the number of cells. Results from three
independent experiments are presented as mean ± SD; *, P<0.008 (Student’s t
test).
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Figure 3.36. Lovastatin did not affect degradation of DQ-collagen IV by
MDA-IBC-3 3D cultures. MDA-IBC-3 cells grown in 3D rBM cultures containing
DQ-collagen IV were treated with Lovastatin (3 µM) or DMSO (vehicle control) for
48 hours. (A) Representative confocal micrographs of the equatorial plane of the
DQ-collagen IV degradation channel (green) and corresponding DIC channel are
shown. Nuclei were stained with Hoechst (blue). Bar, 23 µm. (B) Data are
represented as integrated fluorescence intensity due to proteolysis in the entire
volume of 3D structures and was normalized to the number of cells. Mean ± SD
(n=8).
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Figure 3.37. Lovastatin did not affect degradation of DQ-collagen IV by
SUM190 3D cultures. SUM190 cells grown in 3D rBM cultures containing DQcollagen IV were treated with Lovastatin (3 µM) or DMSO (Control) for 48 hours.
(A) Representative confocal micrographs of the equatorial plane of the DQcollagen IV degradation channel (green) and corresponding DIC channel are
shown. Nuclei were stained with Hoechst (blue). Bar, 24 µm. (B) Data are
represented as integrated fluorescence intensity due to proteolysis in the entire
volume of 3D structures and was normalized to the number of cells. Results
from three independent experiments are presented as mean ± SD.
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Since lovastatin treatment significantly decreased the degradation of
collagen IV by SUM149 cells, we also measured the effect the drug may have on
invasiveness. For these studies, we performed invasion assays as previously
described for the caveolin-1 knockdown studies [see page 76]. Briefly, equal
numbers of SUM149 cells were suspended in serum free media and seeded on
transwell filters coated with rBM.

Medium containing serum, to stimulate

invasion, was added to the chamber below the filter. Cells were incubated with
lovastatin, lovastatin plus exogenous MVA, or DMSO (vehicle control) for 24
hours and the number of invaded cells was counted. Invasion of SUM149 cells
was significantly reduced by lovastatin (Figure 3.38A and B). When MVA was
added in the presence of lovastatin, IBC cells invaded comparably to the vehicle
controls. Invasion assays were also performed with the other IBC cell lines;
however, neither the MDA-IBC-3 or the SUM190 cells invaded under control
conditions, even up to 5 days following their initial seeding.

Mevalonic Acid (MVA) rescues changes in EGFR subcellular
distribution in lovastatin treated IBC cells.

Knockdown of caveolin-1 in

SUM149 cells decreased the localization of EGFR to caveolae-enriched
subcelluar fractions (Figure 3.23). Lovastatin treatment also decreased caveolin1 association with lipid microdomains of SUM149 cells.

To investigate if

lovastatin treatment also exerts this same affect on EGFR, we examined the
subcellular distribution of EGFR in 3D cultures of SUM149 cells. When treated
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Figure 3.38. Lovastatin inhibits invasion of SUM149 cells. SUM149 cells
were subjected to transwell invasion assays in the presence of DMSO (vehicle
control), 3 µM Lovastatin or 3 µM Lovastatin + 1 mM MVA. (A) Images are
SUM149 cells that have invaded through rBM-coated filters; bar, 150 µm. (B)
Quantification of invaded cells was performed by counting the average number of
invaded cells per filter (using Image J software). Results from three independent
experiments are presented as mean ± SD; *, P< 0.001.
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with lovastatin, less EGFR localized to the TI fraction in comparison to DMSO
(vehicle control) controls (Figure 3.39). MVA rescued the observed decreases.
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Figure 3.39. Mevalonic acid (MVA) rescues lovastatin-induced reduction of
EGFR in subcellular fractions of SUM149 3D cultures. SUM149 3D cultures
were isolated by a detergent-based method, as described in Materials and
Methods, that separate Triton X-100-soluble (TS) from Triton X-100–insoluble
(TI) cellular fractions. Equal volume aliquots of each fraction were analyzed by
SDS-PAGE and immunoblotted with antibodies against EGFR and transferrin
receptor (TfR). TfR is a negative control for lipid rafts. MVA rescued this
phenotype.
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CHAPTER 4
DISCUSSION

IBC is a rare but highly aggressive form of breast cancer with symptoms
that develop rapidly (i.e., weeks or months) after initial diagnosis (Vermeulen et
al., 2009). Current treatments for IBC are very limited so new therapeutics are
needed, specifically therapies directed against pathways that mediate the
aggressive IBC phenotype. Proteolytic activity is one important mediator of the
invasion and metastatic spread that are hallmarks of aggressive cancer
(Hanahan and Weinberg, 2011). Proteases of multiple catalytic classes are
associated with caveolae, i.e. serine (Stahl and Mueller, 1995), cysteine
proteases (Cavallo-Medved et al., 2005; Cavallo-Medved et al., 2009) and MMPs
(Annabi et al., 2001; Puyraimond et al., 2001).

Caveolin-1 is a necessary

structural and functional component of caveolae. Caveolin-1 is highly expressed
in and a potential marker of IBC in vivo (Van den Eynden et al., 2006; Nouh et
al., 2011). Our approach in this study was to investigate which proteases
expressed by IBC cells are associated with caveolae, participate in ECM
degradation and invasion by IBC cells and are present in IBC patient samples.
Our findings implicate cathepsin B and uPA as contributors to a proteolytic
pathway that mediates the aggressive IBC phenotype.

Cathepsin B had

previously been shown to activate pro-uPA, a serine protease and member of the
plasminogen cascade involved in ECM degradation, matrix metalloproteinase
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activation and tumor cell invasion (Kobayashi et al., 1991). In SUM149 cells,
uPA and its receptor uPAR colocalize with active cathepsin B in caveolae
(Figures 3.4 and 3.5). The presence of active cathepsin B in caveolae of IBC
cells suggests a potential role for this enzyme in pericellular proteolysis as was
previously shown in colon carcinoma cells (Cavallo-Medved et al., 2005).
Downregulation of caveolin-1 in the colon carcinoma cells decreases cathepsin B
localization to caveolae in parallel with decreases in ECM degradation and cell
invasion (Cavallo-Medved et al., 2005). In the SUM149 cells used in this study,
which express both cathepsin B and caveolin-1, we determined that degradation
of type IV collagen was predominantly pericellular and that a cell impermeant
cathepsin B inhibitor reduced degradation of type IV collagen and invasion
(Figures 3.6 and 3.7).

Although significant, the lack of complete inhibition

suggests that cathepsin B was only one of several proteases in the SUM149
cells that degrade type IV collagen and mediate invasion.

Others have

established that cathepsin B interacts with other proteases in mediating invasion.
For example, Rao and colleagues have demonstrated that downregulation of
both cathepsin B and uPAR more effectively reduces invasion of human glioma
cells in vitro and in vivo in an intracranial xenograft model than does
downregulation of either protease alone. Furthermore, downregulation of both
cathepsin B and matrix metalloproteinase 9 (MMP9) reduces invasion of prostate
tumor cells in vitro and tumor growth in vivo more effectively than downregulation
of either one of the two proteases (Nalla et al., 2010). These studies confirm that
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proteases function in concert, and not alone, to facilitate neoplastic progression.
Proteases

can

exhibit

functional

redundancy,

including

cysteine

cathepsins (Nagler and Menard, 2003; Mohamed and Sloane, 2006). A striking
example occurs between cathepsin B and cathepsin X. Active cathepsin X is
redistributed to the surface of MMTV-PyMT mammary tumor cells deficient in
cathepsin B. Moreover, cathepsin X neutralizing antibodies reduce invasion of
the cathepsin B-deficient mammary tumor cells, consistent with cathepsin X
compensating for the absence of cathepsin B (Vasiljeva et al., 2006).
The studies above illustrate that observations from in vitro assays such as
invasion and ECM degradation assays can be meaningful surrogates for in vivo
tumor endpoints. In a recent collaborative study (N Withana, BF Sloane and BS
Parker, unpublished observations), we demonstrated that either knockdown or
inhibition of cathepsin B in 4T1 mammary carcinoma cells reduced collagen
degradation in vitro, as assessed by our live-cell proteolysis assay, and bone
metastasis in vivo.

Here in the three IBC cell lines, we observed differences in

the degradation of type IV collagen in our live-cell proteolysis assay (Figures 3.2
and 3.36). These differences were further supported by variations in expression
of caveolin-1, cathespin B and uPA, secretion of cathepsin B and uPA and
expression of known caveolae associated proteins, i.e. uPAR and β1-integrin
(Figures 3.1 and 3.24). We propose that these differences may be due, in part,
to the differences in receptor status of the three IBC cell lines. Although all three
lack estrogen and progesterone receptors, only SUM149 is HER2 negative and
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thus a triple negative breast cancer cell line. Triple negative breast cancer is a
subtype of breast cancer characterized as extremely aggressive and having a
poor prognosis due to difficulties in treating and high risks of both recurrence and
death (Dawson et al., 2009; Venkitaraman, 2010). A role for cathepsin B has
previously been reported in several triple negative breast cancer cell lines that
are not IBC (e.g., BT20, BT549, MCF-10AneoT, and MDA-MB-231) (Sameni et
al., 2000; Kos et al., 2005; Gianotti et al., 2008; Gillet et al., 2009); inhibition of
cathepsin B activity in these cells reduced their invasion in vitro. In vivo studies
also provide evidence for an association between cathepsin B and breast
cancers that are triple negative (Prud'homme et al., 2010) (N Withana, BF Sloane
and BS Parker, unpublished observations).

In addition, a transgenic mouse

model of mammary cancer characterized by loss of hormone receptors with
progression of disease (Maglione et al., 2001) exhibits both reduced primary
tumor growth and lung metastases when deficient in cathepsin B (Vasiljeva et al.,
2008), suggesting a link between cathepsin B and metastatic breast disease.
This may be especially true in IBC as expression of cathepsin B was found to be
positively correlated with lymph node metastasis in IBC tissues, a correlation not
observed in non-IBC tissues (Nouh et al., 2011). As such, cathepsin B has been
proposed to be a prognostic marker for IBC and potentially a component of a
proposed molecular signature for IBC (Nouh et al., 2011), a signature that
already includes caveolin-1 (Van den Eynden et al., 2006). Our current findings
show that cathepsin B and caveolin-1 were co-expressed in tumor cells of IBC
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patient samples and not in those of non-IBC patients (Table 3.1). Ongoing work
will determine if this co-expression is elevated in non-IBC triple-negative breast
cancers.
Another enzyme implicated in the aggressive IBC phenotype is RhoC
GTPase, which is increased in expression and activity (Kleer et al., 2004; Wu et
al., 2010).

We speculate that there may be a network that links proteases,

caveolin-1 and Rho signaling pathways in IBC. In colon, prostate and non-IBC
tumors, phosphorylated caveolin-1 has been shown to promote migration and
invasion via a Rho signaling pathway (Joshi et al., 2008); this has not yet been
assessed in IBC. Rho signal transduction pathways have been shown to enrich
localization of mRNAs to cellular protrusions, pseudopodia, thought to play a role
in translation of signaling cascades involved in tumor cell migration and
metastasis (Stuart et al., 2008).

Both cathepsin B and RhoC localize and

function in podosome or invadopodia mediated tumor cell migration and invasion
(Tu et al., 2008; MacGrath and Koleske, 2011). A P132L mutation in caveolin-1
confers a dominant-negative effect on invasiveness of human scirrhous breast
cancers (Hayashi et al., 2001) and upregulates genes involved in invasiveness
and metastasis, including Rho-related signaling molecules and genes expressed
by stem cells (Bonuccelli et al., 2009).

Studies in MDA-MB-231 breast

carcinoma cells connect Rho, caveolin-1 and cathepsin B (Bourguignon et al.,
2004).

Rho kinase signaling events, mediated upstream by CD44-NHE1

interactions localized to lipid microdomains containing caveolin-1, result in
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acidification of the microenvironment surrounding breast cancer cells, activate
secretion of cathepsin B and promote cellular invasiveness. We have previously
shown that slight acidification of the microenvironment of a variety of tumors
(melanoma, colon and breast) increases secretion and activity of cathepsin B
and proteolysis of type IV collagen (Rozhin et al., 1994; Robey et al., 2009;
Rothberg et al., 2011). Whether there is a universal link between Rho, caveolin1, cathepsin B and acidification of the tumor microenvironment has not yet been
evaluated.
One goal of this study was to determine whether cell surface associations
of proteolytic networks in caveolae enhance the aggressiveness of IBC. Our
experimental approach was to downregulate expression of caveolin-1, a
necessary structural and functional component of caveolae, in IBC cells. Two of
the six shRNAmir clones tested, clones C8 and F2, diminished caveolin-1 protein
levels approximately 40 and 95%, respectively (Figure 3.11B). Distribution of
caveolin-1 to lipid enriched fractions was also decreased in knockdown SUM149
cells (Figure 3.14). We hypothesize that loss of caveolin-1 expression correlates
with reduced caveolae biogenesis and thus a loss of caveolae present at the cell
surface of SUM149 cells. This conclusion is consistent with previous reports in
which downregulation of caveolin-1 significantly reduced the number of cell
surface caveolae (Griffoni et al., 2000; Cho et al., 2003).

We found that

knockdown of caveolin-1 did not affect the subcellular distribution of cathepsin B.
These results indicate that cathepsin B localization to lipid microdomains at the
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cell surface of SUM149 cells is independent of caveolin-1 expression. This is
consistent with our findings in the SUM190 and MDA-IBC-3 cell lines, which do
not express caveolin-1.

Cathepsin B is associated with non-caveolar lipid

microdomains of both SUM190 cells (Cavallo-Medved, unpublished data) and
MDA-IBC-3 cells (Figure 3.24).

In contrast, knockdown of caveolin-1 did

decrease the association of both uPA and EGFR with caveolar lipid
microdomains. This suggests that the cell surface associated uPA and EGFR is
mediated by the expression of caveolin-1 in SUM149 cells and that both proteins
compartmentalize in caveolae. The available evidence support that some EGFR
does localize to caveolae (Smart et al., 1995; Mineo et al., 1996). That said,
there is conflict in the literature regarding the quantity of EGFR present in
caveolae and conditions under which EGFR is found in caveolae [for review, see
(Balbis and Posner, 2010)]. Caveolin-1 has been shown to function in uPARdependent activation of integrins α5 and β1, Src and EGFR (Monaghan-Benson
et al., 2008). Monaghan-Benson and colleagues also report that phosphorylated
caveolin-1 directs the trafficking of EFGR to focal adhesions.
Our findings demonstrated that knockdown of caveolin-1 decreased
degradation of DQ-collagen IV and reduced invasion by SUM149 cells (Figures
3.18 and 3.19).

This was true for clone F2, in which there was a greater

reduction of caveolin-1 (cf. Figure 3.11 and Figure 3.14). In other studies,
threshold levels of caveolin-1 protein expression have been shown to be required
for the formation of caveolae at the plasma membrane (Fra et al., 1995; Breuza
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et al., 2002). Perhaps caveolae biogenesis persists in the clone C8 knockdown
cells; verification by means of electron microscopy would be necessary to
validate this hypothesis.
Caveolin-1 oligomers can form functional plasma membranes domains
other than caveolae (Head and Insel, 2007). Caveolin-1 is targeted, in a cell
specific manner, to other intracellular compartments such as secretory vesicles,
mitochondria and the cytoplasm (Li et al., 2001). Caveolin-1 is also a component
of a cytosolic heat-shock protein chaperone complex functioning in transport of
cholesterol from the ER to caveolae (Uittenbogaard et al., 1998). Caveolin-1
complexes with lipoproteins, is localized to the secretory pathway and secreted
by pancreatic and exocrine cells (Liu et al., 1999). In addition, via a scaffolding
domain of 20 amino acids located in the cytosolic N-terminus region, caveolin-1
interacts with several signaling molecules including Src tyrosine kinases, G alpha
subunits, H-Ras, nitric oxide synthase and G-protein-coupled receptors (Li et al.,
1995; Li et al., 1996; Garcia-Cardena et al., 1997). Indeed, multiple functions
have been attributed to caveolin-1 that may be independent of caveolae [for
review, see (Liu et al., 2002a)]. The many other functions of caveolin-1 cannot
be ruled out as possibly contributing to the aggressiveness of IBC and warrant
further investigation.
Our data indicate that the cysteine protease cathepsin B participates in
degradation of type IV collagen and invasion by IBC cells, likely through its
association with proteolytic networks in lipid microdomains at the cell surface.
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Knockdown of caveolin-1 also resulted in decreases in degradation of type IV
collagen and invasion by IBC cells. Our original hypothesis was not valid in that
cathepsin B does not localize specifically to caveolae since downregulating
caveolin-1 did not affect its association with caveolae. Therefore we conclude
that cathepsin B and caveolin-1 both contribute to the aggressiveness of IBC, but
do so by different mechanisms.
Statins directly target the activity of HMG-CoA reductase, the rate-limiting
enzyme in the metabolic pathway that leads to production of cholesterol and
other isoprenoids.

High blood cholesterol is a risk factor for cardiovascular

disease, the number one cause of mortality world wide, and statins are important
in the treatment of this disease (Taylor et al., 2011). Interestingly, statins are
associated with pleiotropic beneficial effects including improvement of endothelial
dysfunction,

increased

nitric

oxide

bioavailability,

antioxidant

and

anti-

inflammatory effects (Davignon, 2004). The multifaceted effects of statins have
led to investigating their potential use in the prevention and treatment of cancer.
Long term statin use for five or more years does not reduce the incidence of most
cancers, including breast cancers (Jacobs et al., 2011). Nonetheless, in vitro
and in vivo studies indicate statins may be a useful therapeutic for treatment of
breast cancer [for review see, (Demierre et al., 2005). Here as an alternative
approach to disrupt lipid microdomains, including caveolae, and thereby test our
hypothesis, we treated IBC cells with a statin drug, lovastatin, to decrease
cholesterol biosynthesis.
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Statins have anti-proliferative affects on breast cancer cells in vitro and in
vivo (Rao et al., 1999; Campbell et al., 2006). In the present study, lovastatin
elicited different effects on IBC proliferation as assessed by MTT assays (Figure
3.25). The MDA-IBC-3 cells were most sensitive to the drug, whereas SUM149
and SUM190 proliferation was unaffected.

Campbell et al. (Campbell et al.,

2006) found that hormone receptor and ErbB2 status may be indicators of
responsiveness to statin treatment.

In a recent clinical trial in which breast

cancer patients were treated with fluvastatin, there was significantly reduced
proliferation and increased apoptosis in tumors that were high grade as
compared to low grade tumors (Garwood et al., 2010).
Cysteine cathepsins, including cathepsin B, play a potentially significant
role in development and progression of many cardiovascular diseases [for
review, see (Lutgens et al., 2007)].

In a murine model of atherosclerosis

increased cathepsin B message and protein levels are associated with highly
inflammatory lesions (Chen et al., 2002) and treatment with statins reduces
cathepsin B expression and activity in these lesions (Kim et al., 2009). These
same effects of statins are not specific to cysteine cathepsins but also extend to
other classes of proteases, including both serine proteases (Denoyelle et al.,
2001) and MMPs (Thunyakitpisal and Chaisuparat, 2004; Abisi et al., 2008). In
our cultures of IBC cells, lovastatin decreased cathepsin B expression and
activity (Figures 3.26 and 3.27). In addition, lovastatin treatment diminished both
the protein level and activity of cathepsin B in both TS and TI fractions of 3D
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cultures of IBC cells (Figures 3.32 and 3.33). These data indicate that lovastatin
is capable of reducing the association of cathepsin B with membrane lipid
microdomains. These findings are particularly interesting because we confirmed
a functional role for cell surface cathepsin B. CA074, a cell impermeable and
highly selective cathepsin B inhibitor, significantly reduced pericellular proteolysis
and invasion by SUM149 cells (Figures 3.6 and 3.7). In agreement with these
findings, lovastatin treatment, which diminished pericellular cathepsin B, also
significantly reduced type IV collagen degradation and invasion by IBC cells
(Figures 3.35 and 3.38).

Others have also shown that lovastatin decreases

migration and invasion of breast cancer cells (Silva et al., 2003; Kang et al.,
2009), in part due to reduced expression of both MMP-2 and -9 (Kang et al.,
2009).

Another statin drug, cerivastatin, inhibits proliferation and invasion of

highly aggressive MDA-MB-231 breast cancer cells, concomitantly with reduced
expression of uPA, MMP-9, uPAR and PAI-1 (Denoyelle et al., 2001; Denoyelle
et al., 2003). In our studies, treatment of SUM149 cells with lovastatin resulted in
decreased uPA expression and secretion (Figure 3.28). The observed reduction
of type IV collagen degradation and invasion by SUM149 cells are a result of
lovastatin-induced decreases in expression of proteases, including cathepsin B
and uPA.
EGFR expression is associated with more aggressive subtypes of breast
cancer and increased expression is also higher in IBC than non-IBC patient
tissues (Guerin et al., 1989). Therapies targeting EGFR (including the use of
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small molecules against its tyrosine kinase domain, e.g. gefitinib and erlotinib, or
cetuximab, a chimeric monoclonal antibody) resulted in little benefit (Rimawi et
al., 2010). This has led to combination strategies to maximize the potential of
drugs and improve patient outcome [for reviews, see (Fischgrabe and Wulfing,
2008; Sanchez-Munoz et al., 2009)]. In comparison to normal cells, cancer cells
are highly dependent on products of the mevalonic pathway and generally have
increased HMG-CoA reductase activity; therefore statins have been proposed for
use as cancer therapeutics (Wong et al., 2002; Chan et al., 2003). In addition,
mevalonate metabolites are also important for EGFR signaling and effects of
statins on EGFR have been investigated.

Lovastatin treatment inhibits

autophosphorylation of EGFR and downstream signaling events (Mantha et al.,
2005; Dimitroulakos et al., 2006); inhibits dimerization of EGFR, decreases both
AKT phosphorylation and inactivation of RhoA (Zhao et al., 2010); and has also
been shown to sensitize resistant cells to drug treatment (Park et al., 2010). In
the current study, we demonstrated that lovastatin treatment of IBC cells reduced
the localization of EGFR to lipid microdomains, which could be rescued by MVA
(Figure 3.39). Irwin et al. have demonstrated that EGFR in lipid microdomains
mediates tyrosine kinase resistance and that treatment with lovastatin causes
decreased Akt phosphorylation in SUM149 cells (Irwin et al., 2011).

Whether

inhibition of downstream signaling is due to disrupted EGFR localization to lipid
microdomains by lovastatin warrants further investigation.
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Stromal components of the IBC tumor microenvironment were not a focus
of the current study.

However, previous findings by our laboratory have

suggested that secreted factors from the conditioned media of human monocytes
increase both expression and activity of cathepsin B in SUM149 cells (Mohamed
et al., 2008).

Monocytes recruited from the circulation into the tumor

microenvironment differentiate into tumor-associated macrophages. The tumorassociated macrophges secrete angiogenic factors and thereby promote tumor
growth and invasion and are associated with poor prognosis in invasive breast
cancer (Leek et al., 1996).

In addition, both tumor cell and macrophage

associated cathepsin B promotes progression and metastatic spread in a murine
model of mammary carcinogenesis (Vasiljeva et al., 2006). Therefore, cathepsin
B is expressed by tumor cells and many other tumor-associated cells, including
macrophages, fibroblasts, endothelial cells, neutrophils and osteoclasts which
contribute to neoplastic progression [for review, see (Mohamed and Sloane,
2006)].

Therefore, statins, by decreasing both expression and activity of

cathepsin B, may prove efficacious in treatment of malignancies associated with
its overexpression and increased activity, such as IBC.

Combinational

therapeutic approaches targeting both cathepsin B and uPAR have been shown
by Rao and colleagues to inhibit tumor progression (Gopinath et al., 2010) and
neovascularization in malignant glioma (Malla et al., 2011). Several protease
targeted drugs are routinely used in the clinic, e.g., ACE inhibitors, and others
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are in pre-clinical development, including neutralizing antibodies against both
cathepsin B and uPA for cancer treatment (for review, see (Turk, 2006)).
This study was undertaken to investigate factors, in particular proteolytic
networks, which mediate the aggressive IBC phenotype. My overall hypothesis
was that cell surface association of the cysteine protease cathepsin B, serine
proteases of the plasminogen cascade and their binding partners in caveolae
enhance cell surface proteolysis, and ultimately, the aggressiveness of IBC cells.
We have demonstrated that there is active cathepsin B at the surface of IBC
cells. Targeting caveolae, a specialized lipid raft, by knockdown of caveolin-1
expression in IBC cells reduces their ability to degrade ECM proteins and their
invasiveness. These studies confirm that caveolin-1 and caveolae play a critical
role in the aggressive phenotype of IBC. In IBC cells that express caveolin-1,
proteases and signaling proteins are associated with caveolae, including uPA
and EGFR. Our studies therefore provide a mechanism for the role of caveolae,
i.e., association of proteolytic pathways with caveolae in IBC cells and
specifically the association of uPA and uPAR, components of the plasminogen
activation system.

We have also demonstrated that targeting lipid rafts by

treating IBC cells with lovastatin alters their aggressive phenotype. In IBC cells
that do not express caveolin-1, we showed that proteases are also associated
with lipid rafts in the plasma membrane.

Those proteases include uPA and

cathepsin B, an upstream activator of pro-uPA. We also confirmed the presence
of EGFR pathways in lipid rafts of IBC cells. Thus, our studies demonstrate a
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critical role for lipid rafts, both caveolar and non-caveolar, in the aggressive
phenotype of IBC.
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Inflammatory breast cancer (IBC) is an aggressive, metastatic and highly
angiogenic form of locally advanced breast cancer. Breast cancer invasion has
been linked to proteolytic activity at the tumor cell surface. We observed that
uPA, uPAR and enzymatically active cathepsin B were all present in caveolae
fractions isolated from SUM149 cells. Using a live-cell proteolysis assay, we
demonstrated that both IBC cell lines degrade type IV collagen. The SUM149
cells exhibit predominantly pericellular proteolysis, consistent with localization of
constituents of a proteolytic pathway to membrane microdomains. A functional
role for cathepsin B was confirmed by the ability of CA074, a cell impermeable
and highly selective cathepsin B inhibitor, to significantly reduce pericellular
proteolysis and invasion by SUM149 cells.

A statistically significant co-

expression of cathepsin B and caveolin-1 was found in IBC patient biopsies, thus
validating our in vitro data. To determine whether the uPA and cathepsin B
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present at the cell surface is localized specifically to caveolae and investigate if
caveolae are a functional component of the IBC phenotype, we knocked down
the expression of caveolin-1 in SUM149 cells. The subcellular distribution of
cathepsin B was unchanged in caveolin-1 knockdown SUM149 cells. In contrast,
knockdown decreased the association of both uPA and EGFR with caveolae.
Knockdown of caveolin-1 also decreased degradation of type IV collagen and
invasion by IBC cells.

We also determined that targeted disruption of lipid

microdomains by use of lovastatin diminished the aggressiveness of IBC cells.
Cathepsin B activity and association with lipid microdomains was reduced in
lovastatin treated IBC cells. Lovastatin treatment also reduced type IV collagen
degradation and invasion by IBC cells.

In conclusion, we have shown that

cathepsin B and caveolin-1 both contribute to the aggressiveness of IBC, albeit
by different mechanisms.
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